Thiohydantoins and use thereof for treating diabetes

Abstract

The invention relates to 2-thiohydantoin derivative compounds selected from compounds of general formula (I): 1

Description

[0001] The present invention relates to novel thiohydantoin (or 2-thioxo-4-imidazolidinone) derivative compounds, their method of preparation and their use as active principles for the preparation of medicaments which are notably intended for treating diabetes.

PRIOR ART

[0002] The chemistry of thiohydantoin-type compounds is known for many years. Certain derivatives of this heterocycle have been used in the field of photography, as described for example in U.S. Pat. No. 2,551,134 or JP 81 111847, or in the field of pesticides, essentially herbicides or fungicides, as described for example in U.S. Pat. No. 3,798,233, in the publications Indian J. Chem.; 1982, Vol 21B, p. 162-164, J. Indian Chem. Soc., Vol 58(10), p. 994-995, Chem. Abst. 67. 82381v, Indian J. Chem., 1979, vol 18B, p. 257-261, and U.S. Pat. No. 4,473,393. More recently, compounds containing a thiohydantoin ring have been prepared with the view to obtaining products which are active in therapeutics. For example, U.S. Pat. No. 3,923,994 describes the use of 3-aryl-2-thiohydantoins for their anti-arthritic activity. U.S. Pat. No. 3,984,430 proposes novel thiohydantoins for treating ulcers. Indian J. Chem. (1978), Vol 16B, p 71-72, describes coumaryl-thiohydantoins which are active against tuberculosis. U.S. Pat. No. 4,312,881 claims acids and esters which comprise a 2-thiohydantoin ring and which have prostaglandin-type activity. Chem. Pharm. Bull., (1982), Vol 30, no 9, p. 3244-3254, describes the inhibition of aldose-reductases by compounds of 1-(phenylsulphonyl)-2-thiohydantoin type. Il Farmaco, Ed Scientifico (1983), Vol 38, no 6, p. 383-390, proposes 3-dialkylaminopropyl-2-thiohydantoins as anti-arrhythmic agents. WO 96/04248 A describes amide- or sulphonamide-type derivatives of 2-thiohydantoin which are antagonists of angiotensin II. WO 97/19932 A claims the use of 2-thiohydantoin derivatives for increasing HDL content. WO 98/33776 cites a bank of compounds which are obtained by combinatorial chemistry and which are tested for their anti-microbial or analgesic properties. Finally, WO 93/18057 and EP 584694 describe acids or esters which comprise a 2-thiohydantoin ring and which are platelet aggregation inhibitors.

[0003] Preparations of compounds comprising a 2-thiohydantoin ring without indication of the industrial usefulness have also been described for example in J. Prakt. Chem., Vol. 333(2), p. 261-266, Indian J. Chem., (1974), vol 12, no 6, p. 577-579, Chem. Abstr., 68 (1968), 87240d, and Organic Magn. Resonance, vol 19, (1) p. 27-30.

AIM OF THE INVENTION

[0004] The present invention relates to novel compounds comprising the heterocycle 2-thiohydantoin (or 2-thioxo-4-imidazolidinone) in their structure, as well as to their method of preparation and their use in therapeutics, notably for the preparation of a medicament intended for treating diabetes, diseases caused by a hyperglycaemia, hypertriglyceridaemiae, dyslipidaemiae, or obesity.

DESCRIPTION

[0005] According to the invention, novel 2-thiohydantoin derivatives are proposed which are selected from:

[0006] a) compounds of formula 2

[0007]  in which

[0008] R1 represents an aromatic ring which is non-substituted or substituted with one or more atoms or groups of atoms selected from halogens, linear or branched C1-C4 alkoxy, linear, branched or cyclic C1-C4 alkyl, linear or branched C1-C4 alkylthio, nitro, trifluoromethyl, trifluoromethoxy, methylenedioxy, or 3

[0009]  groups,

[0010] R2 represents:

[0011] a hydrogen atom,

[0012] a linear, branched or cyclic C1-C7 alkyl group, optionally having one or more oxygen atoms,

[0013] a C1-C3 haloalkyl group,

[0014] a linear or branched C3-C5 alkenyl group,

[0015] a linear or branched C3-C4 alkynyl group,

[0016] a C2-C6 hydroxyalkyl group,

[0017] a C2-C4 aminoalkyl group,

[0018] a C2-C3 cyanoalkyl group,

[0019] a linear or branched C1-C3 alkyl group, which is substituted with one or more R7 substituents, or

[0020] an aromatic ring which is non-substituted or substituted with one or more atoms or groups of atoms selected from halogens, linear or branched C1-C4 alkoxy, linear, branched or cyclic C1-C4 alkyl, linear or branched C1-C4 alkylthio, amino, cyano, hydroxy, nitro, trifluoromethyl, trifluoromethoxy, methylenedioxy, ethylenedioxy, difluoromethylenedioxy, aminosulphonyl, dimethylamino, C1-C3 hydroxyalkyl, carboxylic acid, C2-C3 alkyl ester, methanesulphonylamino, benzenesulphonylamino, t-butoxycarbonylamino, or 4

[0021]  groups,

[0022] R3, R5 and R6 each independently represent a hydrogen atom or a C1-C4 alkyl group,

[0023] R4 represents a hydrogen atom, a C1-C4 alkyl group or a hydroxy group, or,

[0024] R3 and R4 together form a methylene group, or

[0025] R5 and R6 together form an ethylene group —CH2—CH2—,

[0026] R7 represents a carboxylic acid group which is free or esterified with a C1-C3 alkyl group, a phenyl ring which is non-substituted or substituted with one or more methoxy, phenyl or methylenedioxy groups, a 2-furyl ring, a 2-, 3- or 4-pyridinyl ring or a 4-morpholinyl group,

[0027] m=2 or 3,

[0028] X represents an oxygen atom, a sulphur atom, a sulphoxide group, a sulphonyl group, a carbonyl group, a 5

[0029]  group, or a: 6

[0030]  group,

[0031] R8 represents a hydrogen atom, a hydroxy group, a C1-C2 hydroxyalkyl group, a benzoyl group or a CO2CH3 group,

[0032] R9 represents a hydrogen atom or forms, with R8, an ethylenedioxy group, and

[0033] R10 represents a methyl group, a C2-C4 hydroxyalkyl group, a 1-oxo-C2-C4-alkyl group, an SO2N(CH3)2 group, a 2-pyridinyl group or a 2-pyrimidinyl group,

[0034]  on the condition that at least one of the R1 and R2 substituents represents an aromatic ring which is substituted at least with one 7

[0035]  group,

[0036]  and

[0037] b) addition salts of the compounds of formula I with an acid, notably pharmaceutically acceptable salts.

[0038] The invention also comprises, when the R3 and R4 substituents are different, compounds of R-configuration, compounds of S-configuration, and their mixtures.

[0039] The invention also relates to compounds of formula I or their addition salts with an acid, which are pharmaceutically acceptable, for their use as a pharmacologically active substance.

[0040] The invention relates in particular to the use of at least one compound according to formula I above as an active principle for the preparation of a medicament intended for a use in therapeutics, notably for fighting against diseases caused by a hyperglycaemia, diabetes, hypertriglyceridaemiae, dyslipidaemiae or obesity.

DETAILED DESCRIPTION

[0041] In formula I, which represents the compounds of the invention:

[0042] A <<C1-C4 alkyl group >> is understood to be a linear, branched or even cyclic, saturated hydrocarbon chain having 1 to 4 carbon atoms. Examples of C1-C4 alkyl groups include methyl, ethyl, propyl, butyl, 1-methylethyl, cyclopropyl, 1-methylpropyl, 2-methylpropyl, or 1,1-dimethylethyl groups. A << C1-C7 alkyl group optionally having one or more oxygen atoms >> is understood to be a linear, branched or ring-containing, saturated hydrocarbon chain having 1 to 7 carbon atoms, it being possible for said chain to include one or more non-consecutive oxygen atoms between 2 carbon atoms. Examples of C1-C7 alkyl groups optionally having one or more oxygen atoms include the groups which are cited above as well as, notably, pentyl, hexyl, heptyl, 1-methylethyl, cyclohexyl, cyclohexylmethyl, methylcyclohexyl, methoxyethyl, ethoxyethyl, ethoxyethoxyethyl or even tetrahydropyranyloxyalkyl groups.

[0043] When a phenyl group is substituted, the substituent can be located in the ortho, meta or para position, the para position being preferred.

[0044] A << C1-C3 haloalkyl group >> is understood to mean a C1-C3 alkyl group which bears at least one halogen atom selected from fluorine, chlorine or bromine, preferably fluorine, for example a trifluoromethyl or 2,2,2-trifluoroethyl group.

[0045] A <<linear or branched C1-C4 alkoxy group>> is understood to mean methoxy, ethoxy, propoxy, butoxy or 1-methylethoxy groups.

[0046] A <<C3-C5 alkenyl group>> is understood to mean a linear or branched chain which has in its structure a double bond between 2 carbons.

[0047] A <<C3-C4 alkynyl group>> is understood to mean a linear or branched chain which has in its structure a triple bond between 2 carbons.

[0048] A <<C2-C6 hydroxyalkyl group>> is understood to mean an alkyl group having 2 to 6 carbon atoms which is substituted with a hydroxy group. Examples of a C2-C6 hydroxyalkyl group include 2-hydroxyethyl, 2-hydroxypropyl, 3-hydroxypropyl, 4-hydroxybutyl, 5-hydroxypentyl, or 6-hydroxyhexyl groups.

[0049] A <<C2-C4 aminoalkyl group>> is understood to mean an alkyl group having 2 to 4 carbon atoms, which is substituted with an amino group NH2, it being possible for said amino group to be protected by a group of atoms known to the person skilled in the art, e.g. an alkylsulphonyl group or a t-butoxycarbonyl (Boc) group.

[0050] A <<C2-C3 cyanoalkyl group>> is understood to mean an alkyl group having one or two carbon atoms, which is substituted with a cyano group.

[0051] Examples of an aromatic ring are phenyl, 2- or 3-thienyl, 2- or 3-furyl 2-, 3- or 4-pyridinyl, 1- or 2-naphthyl, indolyl, 1-H-imidazolyl, 1-H-benzimidazolyl, benzotriazolyl, 1,3-dihydro-2-oxo-benzimidazolyl, 1,3-dihydro-2-oxo-indolyl, 2H-2-oxo-benzopyranyl, 2H-4H-3-oxo-1,4-benzoxazinyl rings.

[0052] A <<halogen>> is understood to mean fluorine, chlorine or bromine, the preferred halogen atoms in compounds of formula I according to the invention being fluorine and chlorine.

[0053] Compounds of formula I which bear an amine function by the presence of a nitrogen-containing heterocycle or by the presence of an amine substituent, can be salified by a reaction with an acid which is non-toxic and which is acceptable in therapeutics. Mineral acids such as hydrochloric, hydrobromic, phosphoric and sulphuric acids, or organic acids such as methanesulphonic, benzenesulphonic, citric, maleic, fumaric, oxalic, lactic, tartaric or trifluoroacetic acids, can be selected from these acids.

[0054] A preferred family of the compounds of formula (I) of the invention includes:

[0055] a) compounds of formula 8

[0056]  in which

[0057] R1 represents a phenyl ring which is optionally substituted with one or more atoms or groups of atoms selected from halogens, linear C1-C4 alkyl or 9

[0058]  groups,

[0059] R2 represents

[0060] a linear, branched or cyclic C1-C7 alkyl group,

[0061] a linear C3-C5 alkenyl group, or

[0062] a phenyl, 2-thienyl or 3-pyridinyl ring, which is optionally substituted with one or more atoms or groups of atoms selected from halogens, linear or branched C1-C4 alkoxy, linear C1-C4 alkyl, linear C1-C4 alkylthio, amino, hydroxy, nitro, trifluoromethyl, trifluoromethoxy, methylenedioxy or 10

[0063]  groups,

[0064] R4 represents a hydrogen atom, a linear C1-C4 alkyl group, or a hydroxy group,

[0065] R3, R5, and R6 each independently represent a hydrogen atom or a linear C1-C4 alkyl group,

[0066] X represents an oxygen atom, a sulphoxide group or a carbon atom which is substituted with a C1-C2 hydroxyalkyl group,

[0067]  on the condition that at least one of the R1 and R2 substituents represents an aromatic ring which is substituted at least with a 11

[0068]  group,

[0069]  and

[0070] b) addition salts of compounds of formula I with an acid, notably pharmaceutically acceptable salts.

[0071] Compounds of formula I in which R1 represents a phenyl group which is substituted at least in the para position with a 12

[0072] group, are more particularly preferred amongst the compounds of the invention, and from these compounds, those in which X represents an oxygen atom, m=2 and R5 and R6 each represent a hydrogen atom or a methyl group.

[0073] Compounds of formula I in which R3 represents a hydrogen atom and R4 represents a methyl group are also preferred.

[0074] Compounds of formula I can be prepared according to a first general method A which consists in:

[0075] 1) allowing an amino acid of formula: 13

[0076] in which

[0077] R1 represents an aromatic ring which is non-substituted or substituted with one or more atoms or groups of atoms selected from halogens, linear or branched C1-C4 alkoxy, linear, branched or cyclic C1-C4 alkyl, linear or branched C1-C4 alkylthio, nitro, trifluoromethyl, trifluoromethoxy, methylenedioxy or 14

[0078]  groups,

[0079] m represents 2 or 3,

[0080] X represents an oxygen atom, a sulphur atom, a sulphoxide group, a sulphonyl group, a carbonyl group, a 15

[0081]  group, or a: 16

[0082]  group,

[0083] R3, R4, R5 and R6 each independently represent a hydrogen atom or a C1-C4 alkyl group,

[0084] R8 represents a hydrogen atom, a hydroxy group, a C1-C2 hydroxyalkyl group, a benzoyl group or a CO2CH3 group,

[0085] R9 represents a hydrogen atom or forms, with R8, an ethylenedioxy group,

[0086] R10 represents a methyl group, a C2-C4 hydroxyalkyl group, a 1-oxo-C2-C4-alkyl group, an SO2N(CH3)2 group, a 2-pyridinyl group or a 2-pyrimidinyl group,

[0087]  to react with an isothiocyanate of formula

R2—N═C═S  (III)

[0088] in which R2 represents

[0089] a linear, branched or cyclic C1-C7 alkyl group, optionally having one or more oxygen atoms,

[0090] a C1-C3 haloalkyl group,

[0091] a linear or branched C3-C5 alkenyl group,

[0092] a linear or branched C3-C4 alkynyl group,

[0093] a C2-C6 hydroxyalkyl group,

[0094] a protected C2-C4 aminoalkyl group,

[0095] a C2-C3 cyanoalkyl group,

[0096] a linear or branched C1-C3 alkyl group, which is optionally substituted with one or more R7 substituents, or

[0097] an aromatic ring which is non-substituted or substituted with one or more atoms or groups of atoms selected from halogens, linear or branched C1-C4 alkoxy, linear, branched or cyclic C1-C4 alkyl, linear or branched C1-C4 alkylthio, cyano, hydroxy, nitro, trifluoromethyl, trifluoromethoxy, methylenedioxy, ethylenedioxy, difluoromethylenedioxy, aminosulphonyl, dimethylamino, C1-C3 hydroxyalkyl, carboxylic acid, C2-C3 alkyl ester, methanesulphonylamino, benzenesulphonylamino, t-butoxycarbonylamino, or 17

[0098]  groups,

[0099]  in a solvent, such as acetonitrile or dichloromethane for example, in the presence of an aprotic base, notably such as triethylamine, at a temperature of between 10° C. and the reflux temperature of the solvent, for 2 to 4 hours, to obtain the compound of formula I 18

[0100] in which R1, R2, R3, R4 keep the same meaning as above, it being understood that at least one of the R1 and R2 groups contains in its structure an aromatic ring which is substituted at least by the 19

[0101]  group, as defined above;

[0102]  and,

[0103] 2) if necessary, obtaining the addition salt of the compound of formula I above with an organic or mineral acid.

[0104] According to a second method E of preparation of a compound according to the invention, the following steps are carried out, which consist in:

[0105] 1) allowing an amino acid ester of formula (IIa) 20

[0106] in which R1, R3 and R4 have a meaning which is analogous to that of the R1, R3 and R4 substituents which are noted for the compound of formula II which is described in the method A, and Ra represents a C1-C3 alkyl group, preferably an ethyl group,

[0107]  to react with an isothiocyanate of formula

R2—N═C═S  (III)

[0108] as described above for the method A,

[0109]  in a solvent, such as toluene for example, and in the presence of a weak acid, such as acetic acid, at a temperature of between 50° C. and the boiling temperature of the solvent, for 2 to 25 hours, to obtain the compound of formula I 21

[0110] in which R1, R2, R3, R4 keep the same meaning as above, it being understood that at least one of the R1 and R2 groups contains in its structure an aromatic ring which is substituted at least by the 22

[0111]  group, as defined above;

[0112]  and,

[0113] 2) if necessary, obtaining the addition salt of the compound of formula I above with an organic or mineral acid.

[0114] In a variant of step 1) of the method E described above, it is possible for the compounds of formula IIa to be allowed to react according to a method F, which consists in mixing the 2 compounds IIa and III well, without solvent, and in keeping the mixture at a, temperature of about 110 to 130° C., for 0.5 to 3 hours, to obtain the compound of formula I in which R1, R2, R3 and R4 keep the same meaning as in the starting materials.

[0115] According to a second variant M of step 1) of the method E described above, it is possible for the compounds of formula IIa and III to be allowed to react according to a method consisting in mixing the compounds IIa and III well in a tube or a PTFE reactor in the presence of a small amount of acetic acid and heating the mixture for 1 to 15 minutes by means of a microwave radiation, to obtain the compound of formula I in which R1, R2, R3 and R4 keep the same meaning as in the starting materials.

[0116] It is possible for compounds of formula II to be obtained by reaction of an amine of formula

R1—NH2  (IV)

[0117] in which R1 represents the same meaning as above, with a halogen-containing acid of formula 23

[0118] in which Hal represents a halogen, preferably bromine, R3 and R4 each independently represent a hydrogen atom or a C1-C4 alkyl group,

[0119] preferably in the absence of solvent and in the presence of sodium bicarbonate, at a temperature of between 60 and 140° C., for 0.5 to 10 hours, in order to obtain the acid of formula 24

[0120] in which R1, R3 and R4 keep the same meaning as in the starting materials,

[0121] It is possible for compounds of formula IIa to be obtained by reaction of an amine of formula

R1—NH2  (IV)

[0122] in which R1 represents the same meaning as above, with an α-halogenated ester of formula 25

[0123] in which Hal represents a halogen, preferably bromine, Ra represents a C1-C3 alkyl group, preferably an ethyl group, R3 and R4 each independently represent a hydrogen atom or a C1-C4 alkyl group,

[0124] in a solvent such as ethanol, in the presence of sodium acetate, at a temperature of between 50° C. and the reflux temperature of the solvent, for 2 to 20 hours to obtain the compound of formula 26

[0125] in which R1, Ra, R3 and R4 keep the same meaning as in the starting materials.

[0126] The compounds of formula III

R2—N═C═S  (III)

[0127] are in general commercial products or can be prepared by following methods which are known to the person skilled in the art, e.g. by reduction of a nitrite compound R2—NO2, so as to obtain the primary amine R2—NH2, which is then allowed to react for example with thiocarbonyldiimidazole in order to obtain the corresponding isothiocyanate.

[0128] It is possible for compounds of formula I in which R4 represents a hydroxy group to be obtained from compounds of formula (I) in which R4 is a hydrogen atom, by careful oxidation by means of air oxygen in a solvent such as dimethylsulphoxide (DMSO) for example.

[0129] It is possible for compounds of formula I in which one of the R1 or R2 groups comprises a primary or secondary amino substituent to be obtained according to a method analogous to methods A and E described above, by using starting materials which bear an amino group protected with an amino-protecting group such as a Boc (t-butyloxycarbonyl) group for example, said protecting group being removed by means known to the person skilled in the art, after obtaining the cyclised compound of central 2-thioxo-4-imidazolidinone structure.

[0130] It is possible for compounds of formula I in which X represents an S═O group to be obtained starting from the compounds of formula IIa in which X represents a sulphur atom, by careful oxidation by means for example of a urea/hydrogen peroxide complex, by carrying out the reaction in a solvent such as methanol for example, in the presence of phthalic anhydride, and then a reaction of the ester thus obtained with an isothiocyanate of formula III in accordance with the teaching of method E described above.

[0131] Most of the compounds according to the invention have one or more carbon atoms having asymmetry. In the present description, if no indication is specified in the nomenclature, the compound is a racemic compound, i.e. containing R and S isomers in roughly equal amounts. In the case of compounds the asymmetric carbon(s) of which is (are) in a specific configuration, the R or S configuration is indicated corresponding to the position of the substituent introducing the asymmetric centre.

[0132] In the examples which follow, the term <<preparation>> designates the examples which describe the synthesis of intermediate compounds, and the term <<Examples>> designates those which describe the synthesis of compounds of formula (I) according to the invention. The aim of these examples is to illustrate the invention: they do not in any way limit the scope of the invention. Melting points are measured on a Koffler block and the spectral values of nuclear magnetic resonance are characterised by the chemical shift calculated with respect to TMS, by the number of protons associated with the signal and by the form of the signal (s for singlet, d for doublet, t for triplet, q for quadruplet, m for multiplet). The working frequency and the solvent used are indicated for each compound.

[0133] Preparation I

[0134] N-[4-(4-morpholinyl)phenyl]alanine, Ethyl Ester

[0135] A solution of 100 g (0.56 M) of 4-(4-morpholinyl)aniline in 3 l of absolute ethanol is prepared, and 69 g (0.84 M) of sodium acetate, then 109 ml (0.84 M) of ethyl 2-bromopropionate, are added. The reaction mixture is then agitated for 16 hours under reflux of the solvent. After cooling, the mixture is filtered and the filtrate is concentrated under reduced pressure. The residue is taken up into 1.5 l of ethyl acetate and the solution obtained is washed with an aqueous solution of sodium chloride. The organic phase is dried over magnesium sulphate, and then concentrated under reduced pressure. The residue is taken up into 0.8 l of isopropyl ether and the solid obtained is isolated by filtration and then dried. 108 g of the product sought after are thus obtained as a fine beige solid (yield=69%).

[0136] M PT.=90° C.

[0137] Preparation II

[0138] N-[4-(4-morpholinyl)phenyl]alanine, Dihydrochloride

[0139] A solution of 20 g (71.9 mM) of the ester obtained according to preparation I in 200 ml of tetrahydrofuran is prepared and 84 ml of a normal solution of lithia in water are added. The mixture is agitated for 2 hours at ambient temperature and then the solvent is removed under reduced pressure. The residual aqueous phase is washed 3 times with 100 ml of ethyl ether and then cooled and acidified with 21.6 ml of 10N hydrochloric acid. The mixture is concentrated under reduced pressure until the appearance of crystals. This solid is separated off by filtration and washed on the filter with acetone. After drying, 25.6 g of the product sought after are obtained as a pink solid (the product contains a little lithium chloride).

[0140] 1 H NMR (DMSO d6, 300 MHz): 1.38 (d, 3H); 3.48 (m, 4H); 4.05 (m, 4H); 4.07 (q,1H); 6.75 (d,2H); 7.53 (d,2H).

[0141] Preparation III

[0142] 3-[4-[(1,1-dimethylethoxycarbonyl)amino]phenyl]-1-[4-(4-morpholinyl)phenyl]-5-methyl-2-thioxo-4-imidazolidinone

[0143] 450 mg (1.6 mM) of the ester obtained according to preparation 1 and 410 mg of 4-[(1,1-dimethylethoxycarbonyl)amino]phenyl isothiocyanate are mixed in 10 ml of toluene and 0.4 ml of acetic acid are added. The mixture is agitated at the reflux temperature of the solvent for 5 hours and then cooled to 10-15° C. The white precipitate formed is separated off by filtration, rinsed with 2 ml of cold toluene and then dried under reduced pressure. 720 mg of the product sought after are thus obtained as white crystals (yield=80%).

[0144] M PT.=224-226° C.

[0145] Preparation IV

[0146] 3-(trifluoromethoxy)phenyl Isothiocyanate

[0147] A solution of 3.46 g (19.5 mM) of 3-(trifluoromethoxy)aniline in 150 ml of dimethylformamide is prepared and is cooled to 0° C. A solution of 3.83 g (21.45 mM) of thiocarbonyldiimidazole dissolved in 60 ml of dimethylformamide is then added dropwise. The reaction mixture is agitated at ordinary temperature for 1 hour 30 minutes, then poured onto 300 ml of water, and extracted with twice 100 ml of ethyl ether. These organic phases are washed with twice 50 ml of water, dried over magnesium sulphate and then concentrated under reduced pressure. This residue is purified by chromatography on silica gel in eluting with the aid of a cyclohexane/ethyl acetate mixture (95/5; v/v). 2.1 g of product sought after are thus obtained as a green-yellow liquid (yield=50%).

[0148] 1 H NMR (CDCl3, 300 MHz): 7.38 (t, 1H); 7.15 (m, 3H)

[0149] Preparation V

[0150] N-[4-(4-morpholinyl)-2-methylphenyl]alanine, Ethyl Ester

[0151] In performing analogously to preparation I, starting with 4-(4-morpholinyl)-2-methylaniline, the product sought after is obtained as a yellow powder (yield=78%).

[0152] M PT.=70° C.

[0153] Preparation VI

[0154] N-[3,5-dimethyl-4-(4-morpholinyl)phenyl]alanine, Ethyl Ester

[0155] In performing analogously to preparation I, starting with 3,5-dimethyl-4-(4-morpholinyl)aniline, the product sought after is obtained as a beige oil (yield=91%).

[0156] 1 H NMR (CDCl3, 300 MHz): 6.25 (s, 2H); 4.20 (m, 3H); 4.07 (m, 1H); 3.75 (t,4H); 3.02 (t,4H); 2.25 (s,6H); 1.49 (d, 3H); 1.28 (t, 3H).

[0157] Preparation VII

[0158] N-[3,5-dichloro-4-(4-morpholinyl)phenyl]alanine

[0159] A mixture of 1.66 g (6.72 mM) of 3,5-dichloro-4-(4-morpholinyl)aniline, 2 g (23.5 mM) of sodium bicarbonate and 1.25 ml (13.44 mM) of 2-bromopropanoic acid is prepared and the reaction mixture is agitated at 100° C. for 4 hours. The mixture is then cooled and then taken up into 60 ml of ethyl acetate and 40 ml of water, and then brought to slightly acidic pH with the aid of an N solution of hydrochloric acid. The separated aqueous phase is extracted with ethyl acetate and the combined organic phases are washed with a solution of sodium chloride and then dried over magnesium sulphate and concentrated under reduced pressure. The crude product thus obtained is used without further purification for the following syntheses.

[0160] Preparation VIII

[0161] N-[4-(2S,6S-dimethyl-4-morpholinyl)phenyl]alanine, ethyl ester

[0162] In performing analogously to preparation I, starting with 4-(2S,6S-dimethyl-4-morpholinyl)aniline, the product sought after is obtained as a yellow oil (yield=87%).

[0163] 1 H NMR (CDCl3, 300 MHz): 6.81 (d, 2H); 6.63 (d, 2H); 4.15 (m, 5H); 3.9 (m,1H); 3.08 (2d,2H); 2.75 (2d,2H); 1.48 (d, 3H); 1.32 (d, 6H); 1.30 (t, 3H).

[0164] Preparation IX

[0165] N-[4-(2R,6S-dimethyl-4-morpholinyl)phenyl]alanine, Ethyl Ester

[0166] In performing analogously to preparation I, starting with 4-(2R,6S-dimethyl-4-morpholinyl)aniline, the product sought after is obtained as a pale yellow paste (yield=84%).

[0167] 1 H NMR (CDCl3, 300 MHz): 6.82 (d, 2H); 6.59 (d, 2H); 4.17 (q, 2H); 4.07 (m, 1H); 3.85 (m, 3H); 3.25 (d, 2H); 2.33 (t, 2H); 1.45 (d, 3H); 1.24 (t, 3H); 1.23 (d, 6H).

[0168] Preparation X

[0169] 2-methyl-N-[4-(4-morpholinyl)phenyl]alanine, Ethyl Ester

[0170] In performing analogously to preparation I, starting with ethyl 2-bromo-2-methylpropanoate, the product sought after is obtained as beige crystals (yield=70%).

[0171] M PT.=78° C.

[0172] Preparation XI

[0173] 1-(4-nitrophenyl)-4-piperidinemethanol

[0174] A solution of 1.4 g (10 mM) of 4-fluoro-1-nitrobenzene in 20 ml of dimethylsulphoxide is prepared and 2.5 g (22 mM) of 4-piperidinemethanol are added. The reaction mixture is kept under agitation for 1 hour at 80° C. and then cooled and poured onto 200 ml of water. The yellow precipitate formed is separated off by filtration, washed with water and dried. 2.3 g of the product sought after are thus obtained as a white powder (yield=99%).

[0175] M PT.=161° C.

[0176] Preparation XII

[0177] 1-(4-aminophenyl)-4-piperidinemethanol

[0178] A solution of 2.3 g of the compound obtained according to preparation XI in 150 ml of methanol is prepared and 200 mg de 10% palladium on carbon are added. The mixture is agitated under a hydrogen atmosphere for 1 hour 30 minutes, under atmospheric pressure and at ambient temperature. The catalyst is then separated off by filtration and the filtrate is concentrated under reduced pressure. 2 g of the product sought after are thus obtained as a beige powder (yield=99%).

[0179] M PT.=105° C.

[0180] Preparation XIII

[0181] N-[4-[4-(hydroxymethyl)-1-piperidinyl]phenyl]alanine, Dihydrochloride

[0182] A solution of 1.95 g of the compound obtained according to preparation XII and 2 ml of 2-bromopropanoic acid is prepared and 2.78 g (33.2 mM) of sodium bicarbonate are added. The reaction mixture is kept under agitation for 30 minutes at 100° C., and then cooled and dissolved in 100 ml of water. The solution is acidified to pH 1 with the aid of hydrochloric acid and this aqueous phase is washed with 50 ml of dichloromethane and then concentrated under reduced pressure. 3.9 g of the non-purified acid sought after are thus obtained, as beige crystals which are used directly in the next step without other purification.

[0183] Preparation XIV

[0184] N-[4-(4-thiomorpholinyl)phenyl]alanine, Ethyl Ester

[0185] In performing analogously to preparation I, starting with 4-(4-thiomorpholinyl)aniline, the product sought after is obtained as a white powder (yield=48%).

[0186] M PT.=240° C.

[0187] Preparation XV

[0188] N-[4-(4-thiomorpholinyl)phenyl]alanine, Ethyl Ester, S-Oxide

[0189] A solution of 0.13 g (1.36 mM) of the urea/hydrogen peroxide addition compound in 4 ml of methanol is prepared and 0.05 g (0.34 mM) of phthalic anhydride, and then 0.2 g (0.68 mM) of the ester obtained according to preparation XIV, are added. The reaction mixture is kept under agitation for 1 hour 30 minutes at ambient temperature, and then poured onto 50 ml of water. The mixture is extracted with twice 50 ml of ethyl acetate and the combined organic phases are then washed with water and then dried over magnesium sulphate and concentrated under reduced pressure. The residue is purified by chromatography on silica gel in eluting with the aid of a dichloromethane/methanol mixture (99/1; v/v). 80 mg of the product sought after are thus obtained (yield=38%).

[0190] Preparation XVI

[0191] N-[4-(4-morpholinyl)phenyl]glycine, Dihydrochloride

[0192] 10 g (57 mM) of 4-(4-morpholinyl)aniline and 16.5 g of sodium bicarbonate are mixed well. 9.4 g (67 mM) of bromoacetic acid are added. The mixture is agitated at 120° C. for 6 minutes and then cooled and poured onto 100 ml of water. The aqueous phase obtained is washed with 50 ml of dichloromethane and then slowly acidified to pH 1 with hydrochloric acid. The aqueous phase is concentrated under reduced pressure and the solid residue is triturated with 100 ml of a dichloromethane/methanol mixture (80/20; v/v). The mixture is filtered and the filtrate concentrated under reduced pressure enables 16 g of brown crystals to be obtained which are used without further purification for the next step.

[0193] Preparations XVII to LXXX relating to novel intermediates which are useful for the synthesis of compounds of formula (I), and which are in general obtained according to methods analogous to those of the preceding preparations or according to methods described further on (such as method P), are grouped in Table II, situated further on.

EXAMPLE 1

[0194] 3-(4-methoxyphenyl)-5-methyl-1-[4-(4-morpholinyl)phenyl]-2-thioxo-4-imidazolidinone

[0195] A solution of 45 g (0.16 M) of the compound obtained according to preparation I in 400 ml of toluene is prepared and 36.3 g (0.22 M) of 4-(isothiocyanato)anisole, and then 20 ml of acetic acid, are added. The reaction mixture is then kept under reflux for 16 hours. The reaction medium is concentrated under reduced pressure and the residue is purified by chromatography on silica gel in eluting with the aid of a toluene/ethyl acetate mixture (80/20; v/v). 53 g of the product sought after are thus obtained as a pale yellow solid (yield=82.5%).

[0196] M PT.=181° C.

EXAMPLE 2

[0197] 5-methyl-1-[4-(4-morpholinyl)phenyl]-3-phenyl-2-thioxo-4-imidazolidinone

[0198] In performing analogously to Example 1, starting with phenyl isothiocyanate, the product sought after is obtained as a pale yellow powder (yield=77%).

[0199] M PT.=214° C.

EXAMPLE 3

[0200] 5-methyl-1-[4-(4-morpholinyl)phenyl]-3-phenyl-2-thioxo-4-imidazolidinone, Hydrochloride

[0201] 1 g (2.72 mM) of the compound obtained according to Example 2 is dissolved in 5 ml of dichloromethane. The solution is cooled to 0° C. and then 1.3 ml of a saturated ethylic solution of hydrogen chloride are added. The white precipitate is separated off by filtration, washed with a little ethyl ether and dried under reduced pressure. 1.1 g of the product sought after are thus obtained as a white powder (yield=99%).

[0202] M PT.=212° C.

EXAMPLE 4

[0203] 3-(4-hydroxyphenyl)-5-methyl-1-[4-(4-morpholinyl)phenyl]-2-thioxo-4-imidazolidinone

[0204] In performing analogously to Example 1, starting with 4-(isothiocyanato)-phenol, the product sought after is obtained as a white powder (yield=52%).

[0205] M PT.=220° C.

EXAMPLE 5

[0206] 5-methyl-3-(3-methoxyphenyl)-1-[4-(4-morpholinyl)phenyl]-2-thioxo-4-imidazolidinone

[0207] In performing analogously to Example 1, starting with 3-methoxyphenyl isothiocyanate, the product sought after is obtained as beige crystals (yield=58%).

[0208] M PT.=175° C.

EXAMPLE 6

[0209] 3-(4-ethoxyphenyl)-5-methyl-1-[4-(4-morpholinyl)phenyl]-2-thioxo-4-imidazolidinone

[0210] In performing analogously to Example 1, starting with 4-ethoxyphenyl isothiocyanate, the product sought after is obtained as white crystals with a yield of 48%.

[0211] M PT.=180-182° C.

EXAMPLE 7

[0212] 3-(4-chlorophenyl)-5-methyl-1-[4-(4-morpholinyl)phenyl]-2-thioxo-4-imidazolidinone

[0213] 0.6 g (2 mM) of the acid obtained according to preparation II are dissolved in 5 ml of dichloromethane and 0.1 g of triethylamine and 0.68 g (4 mM) of 4-chlorophenyl isothiocyanate are added. The reaction mixture is kept under agitation for 20 hours at ambient temperature, and then concentrated under reduced pressure. The residue is purified by chromatography on silica gel in eluting with the aid of a dichloromethane/ethyl acetate mixture (96/4; v/v). 0.37 g of the product sought after are thus obtained as a white powder (yield=46%).

[0214] M PT.=212° C.

EXAMPLE 8

[0215] 3-(3-chlorophenyl)-5-methyl-1-[4-(4-morpholinyl)phenyl]-2-thioxo-4-imidazolidinone

[0216] In performing analogously to Example 1, starting with 3-chlorophenyl isothiocyanate, the product sought after is obtained as beige crystals (yield=54%).

[0217] M PT.=137-138° C.

EXAMPLE 9

[0218] 3-(2-chlorophenyl)-5-methyl-1-[4-(4-morpholinyl)phenyl]-2-thioxo-4-imidazolidinone

[0219] In performing analogously to Example 7, starting with 2-chlorophenyl isothiocyanate, the product sought after is obtained as yellow crystals (yield=35%).

[0220] M PT.=116° C.

EXAMPLE 10

[0221] 3-(4-fluorophenyl)-5-methyl-1-[4-(4-morpholinyl)phenyl]-2-thioxo-4-imidazolidinone

[0222] In performing analogously to Example 1, starting with 4-fluorophenyl isothiocyanate, the product sought after is obtained as white crystals (yield=52%).

[0223] M PT.=188-190° C.

EXAMPLE 11

[0224] 3-(3-fluorophenyl)-5-methyl-1-[4-(4-morpholinyl)phenyl]-2-thioxo-4-imidazolidinone

[0225] In performing analogously to Example 1, starting with 3-fluorophenyl isothiocyanate, the product sought after is obtained as cream-coloured crystals (yield=74%).

[0226] M PT.=196-198 C

EXAMPLE 12

[0227] 3-(2-fluorophenyl)-5-methyl-1-[4-(4-morpholinyl)phenyl]-2-thioxo-4-imidazolidinone

[0228] In performing analogously to Example 1, starting with 2-fluorophenyl isothiocyanate, the product sought after is obtained as yellow crystals (yield=58%).

[0229] M PT.=186-188° C.

EXAMPLE 13

[0230] 5-methyl-3-(3-methylphenyl)-1-[4-(4-morpholinyl)phenyl]-2-thioxo-4-imidazolidinone

[0231] In performing analogously to Example 1, starting with 3-methylphenyl isothiocyanate, the product sought after is obtained as beige crystals (yield=46%).

[0232] M PT.=160-162° C.

EXAMPLE 14

[0233] 5-methyl-3-(2-methylphenyl)-1-[4-(4-morpholinyl)phenyl]-2-thioxo-4-imidazolidinone

[0234] In performing analogously to Example 1, starting with 2-methylphenyl isothiocyanate, the product sought after is obtained as white crystals (yield=9%).

[0235] M PT.=143-145° C.

EXAMPLE 15

[0236] 5-methyl-1-[4-(4-morpholinyl)phenyl]-3-(4-nitrophenyl)-2-thioxo-4-imidazolidinone

[0237] In performing analogously to Example 1, starting with 4-nitrophenyl isothiocyanate, the product sought after is obtained as yellow crystals (yield=88%).

[0238] M PT.=208-210° C.

EXAMPLE 16

[0239] 3-(4-aminophenyl)-5-methyl-1-[4-(4-morpholinyl)phenyl]-2-thioxo-4-imidazolidinone

[0240] 500 mg of the compound obtained according to preparation III are dissolved in 90 ml of dichloromethane, 10 ml of trifluoroacetic acid are added and then this mixture is agitated for one hour at 20° C. The reaction mixture is then concentrated under reduced pressure and the residue is taken up into suspension in 100 ml of a saturated solution of sodium bicarbonate. This suspension is extracted with dichloromethane and the organic phase obtained is concentrated under reduced pressure. The residue is purified by chromatography on silica gel in eluting with the aid of a dichloromethane/methanol mixture (96/4; v/v). 400 mg of the product sought after are thus obtained as white crystals (yield=95%).

[0241] M PT.=269-270° C.

EXAMPLE 17

[0242] 5-methyl-3-[4-(methylthio)phenyl]-1-[4-(4-morpholinyl)phenyl]-2-thioxo-4-imidazolidinone

[0243] In performing analogously to Example 1, starting with 4-(methylthio)phenyl isothiocyanate, the product sought after is obtained as cream-coloured crystals (yield=77%).

[0244] M PT.=168-170° C.

EXAMPLE 18

[0245] 5-methyl-3-[4-(1-methylethoxy)phenyl]-1-[4-(4-morpholinyl)phenyl]-2-thioxo-4-imidazolidinone

[0246] In performing analogously to Example 1, starting with 4-(1-methylethoxy)phenyl isothiocyanate, the product sought after is obtained as a cream-coloured powder (yield=60%).

[0247] M PT.=120-122 C

EXAMPLE 19

[0248] 5-methyl-1-[4-(4-morpholinyl)phenyl]-2-thioxo-3-[3-(trifluoromethoxy)-phenyl]-4-imidazolidinone

[0249] In performing analogously to Example 1, starting with 3-(trifluoromethoxy)phenyl isothiocyanate, the product sought after is obtained as a brown powder (yield=56%).

[0250] M PT.=84-88° C.

EXAMPLE 20

[0251] 5-methyl-1-[4-(4-morpholinyl)phenyl]-2-thioxo-3-[3-(trifluoromethyl)-phenyl]-4-imidazolidinone

[0252] In performing analogously to Example 1, starting with 3-(trifluoromethyl)phenyl isothiocyanate, the product sought after is obtained as cream-coloured crystals (yield=70%).

[0253] M PT.=163-165° C.

EXAMPLE 21

[0254] 3-(3,4-dimethoxyphenyl)-5-methyl-1-[4-(4-morpholinyl)phenyl]-2-thioxo-4-imidazolidinone

[0255] In performing analogously to Example 1, starting with 3,4-(dimethoxy)phenyl isothiocyanate, the product sought after is obtained as a pale yellow fluffy solid (yield=35%).

[0256] M PT.=214-216° C.

EXAMPLE 22

[0257] 3-(2,4-dimethoxyphenyl)-5-methyl-1-[4-(4-morpholinyl)phenyl]-2-thioxo-4-imidazolidinone

[0258] In performing analogously to Example 1, starting with 2,4-(dimethoxy)phenyl isothiocyanate, the product sought after is obtained as orange crystals (yield=31%).

[0259] M PT.=110° C.

EXAMPLE 23

[0260] 5-methyl-3-(3,4-methylenedioxyphenyl)-1 [4-(morpholinyl)phenyl]-2-thioxo-4-imidazolidinone

[0261] In performing analogously to Example 1, starting with 3,4-(methylenedioxy)phenyl isothiocyanate, the product sought after is obtained as a yellow fluffy solid (yield=55%).

[0262] M PT.=223-225° C.

EXAMPLE 24

[0263] 3-(4-methoxy-2-nitrophenyl)-5-methyl-1-[4-(4-morpholinyl)phenyl]-2-thioxo-4-imidazolidinone

[0264] In performing analogously to Example 1, starting with 4-methoxy-2-nitrophenyl isothiocyanate, the product sought after is obtained as beige crystals (yield=56%).

[0265] M PT.=178-180° C.

EXAMPLE 25

[0266] 3-(4-methoxy-2-methylphenyl)-5-methyl-1-[4-(4-morpholinyl)phenyl]-2-thioxo-4-imidazolidinone

[0267] In performing analogously to Example 7, starting with 4-methoxy-2-methylphenyl isothiocyanate, the product sought after is obtained as cream-coloured crystals (yield=12%).

[0268] M PT.=144-146° C.

EXAMPLE 26

[0269] 3-(3,4-difluorophenyl)-5-methyl-1-[4-(4-morpholinyl)phenyl]-2-thioxo-4-imidazolidinone

[0270] In performing analogously to Example 1, starting with 3,4-difluorophenyl isothiocyanate, the product sought after is obtained as a white powder (yield=62%).

[0271] M PT.=164-165° C.

EXAMPLE 27

[0272] 5-methyl-1-[4-(4-morpholinyl)phenyl]-3-(3-pyridinyl)-2-thioxo-4-imidazolidinone

[0273] In performing analogously to Example 1, starting with 3-pyridinyl isothiocyanate, the product sought after is obtained as cream-coloured crystals (yield=15%).

[0274] M PT.=152-154° C.

EXAMPLE 28

[0275] 5-methyl-1-[4-(4-morpholinyl)phenyl]-3-(2-thienyl)-2-thioxo-4-imidazolidinone

[0276] In performing analogously to Example 1, starting with 2-thienyl isothiocyanate, the product sought after is obtained as a beige powder (yield=35%).

[0277] M PT.=184-185° C.

EXAMPLE 29

[0278] 3-ethyl-5-methyl-1-[4-(4-morpholinyl)phenyl]-2-thioxo-4-imidazolidinone

[0279] In performing analogously to Example 1, starting with ethyl isothiocyanate, the product sought after is obtained as a yellow powder (yield=61%).

[0280] M PT.=126° C.

EXAMPLE 30

[0281] 5-methyl-1-[4-(4-morpholinyl)phenyl]-3-(2-propenyl)-2-thioxo-4-imidazolidinone

[0282] In performing analogously to Example 1, starting with 2-propenyl isothiocyanate, the product sought after is obtained as an off-white powder (yield=54%).

[0283] M PT.=106° C.

EXAMPLE 31

[0284] 3-(cyclopentyl)-5-methyl-1-[4-(4-morpholinyl)phenyl]-2-thioxo-4-imidazolidinone

[0285] In performing analogously to Example 1, starting with cyclopentyl isothiocyanate, the product sought after is obtained as a white solid (yield=41%).

[0286] M PT.=148-149° C.

EXAMPLE 32

[0287] 5-methyl-1-[4-(4-morpholinyl)-2-methylphenyl]-3-phenyl-2-thioxo-4-imidazolidinone

[0288] In performing analogously to Example 2, starting with the ester obtained according to preparation V, the product sought after is obtained as a beige powder (yield=36%).

[0289] M PT.=180° C.

EXAMPLE 33

[0290] 1-[3,5-dimethyl-4-(4-morpholinyl)phenyl]-3-(4-methoxyphenyl)-5-methyl-2-thioxo-4-imidazolidinone

[0291] In performing analogously to Example 1, starting with the ester obtained according to preparation VI, the product sought after is obtained as an off-white powder (yield=48%).

[0292] M PT.=240 C

EXAMPLE 34

[0293] 1-[3,5-dichloro-4-(4-morpholinyl)phenyl]-5-methyl-3-phenyl-2-thioxo-4-imidazolidinone

[0294] In performing analogously to Example 7, starting with the acid obtained according to preparation VII, the product sought after is obtained as a white powder (yield=16%).

[0295] M PT.=255° C.

EXAMPLE 35

[0296] 1-[4-(2S,6S-dimethyl-4-morpholinyl)phenyl]-5-methyl-3-phenyl-2-thioxo-4-imidazolidinone

[0297] In performing analogously to Example 2, starting with the ester obtained according to preparation VIII, the product sought after is obtained as a white powder (yield=80%).

[0298] M PT.=184° C.

EXAMPLE 36

[0299] 1-[4-(2R,6S-dimethyl-4-morpholinyl)phenyl]-5-methyl-3-phenyl-2-thioxo-4-imidazolidinone

[0300] In performing analogously to Example 2, starting with the ester obtained according to preparation IX, the product sought after is obtained as a white powder (yield=85%).

[0301] M PT.=200° C.

EXAMPLE 37

[0302] 1-[4-(2R,6S-dimethyl-4-morpholinyl)phenyl]-3-(4-methoxyphenyl)-5-methyl-2-thioxo-4-imidazolidinone

[0303] In performing analogously to Example 1, starting with the ester obtained according to preparation IX, the product sought after is obtained as a pale yellow powder (yield=63%).

[0304] M PT.=210° C.

EXAMPLE 38

[0305] 1-[4-(2R,6S-dimethyl-4-morpholinyl)phenyl]-3-(3-fluorophenyl)-5-methyl-2-thioxo-4-imidazolidinone

[0306] In performing analogously to Example 37, starting with 3-fluorophenyl isothiocyanate, the product sought after is obtained as a white powder (yield=96%).

[0307] M PT.=217° C.

EXAMPLE 39

[0308] 5,5-dimethyl-1-[4-(4-morpholinyl)phenyl]-3-phenyl-2-thioxo-4-imidazolidinone

[0309] In performing analogously to Example 2, starting with the ester obtained according to preparation X, the product sought after is obtained as a beige powder (yield=23%).

[0310] M PT.=206° C.

EXAMPLE 40

[0311] 5,5-dimethyl-3-(4-methoxyphenyl)-1-[4-(4-morpholinyl)phenyl]-2-thioxo-4-imidazolidinone

[0312] In performing analogously to Example 1, starting with the ester obtained according to preparation X, the product sought after is obtained as a white powder (yield=30%).

[0313] M PT.=225-230° C.

EXAMPLE 41

[0314] 5,5-dimethyl-3-(3-fluorophenyl)-1-[4-(4-morpholinyl)phenyl]-2-thioxo-4-imidazolidinone

[0315] In performing analogously to Example 11, starting with the ester obtained according to preparation X, the product sought after is obtained as a beige powder (yield=60%).

[0316] M PT.=219° C.

EXAMPLE 42

[0317] 3-(3-chlorophenyl)-5,5-dimethyl-1-[4-(4-morpholinyl)phenyl]-2-thioxo-4-imidazolidinone

[0318] In performing analogously to Example 8, starting with the ester obtained according to preparation X, the product sought after is obtained as white crystals (yield=32%).

[0319] M PT.=220° C.

EXAMPLE 43

[0320] 5,5-dimethyl-3-(3,4-methylenedioxyphenyl)-1-[4-(4-morpholinyl)phenyl]-2-thioxo-4-imidazolidinone

[0321] In performing analogously to Example 23, starting with the ester obtained according to preparation X, the product sought after is obtained as white crystals (yield=24%).

[0322] M PT.=202° C.

EXAMPLE 44

[0323] 1-[4-[4-(hydroxymethyl)-1-piperidinyl]phenyl}-3-(4-methoxyphenyl)-5-methyl-2-thioxo-4-imidazolidinone

[0324] A solution of 1 g (3.6 mM) of the amino acid obtained according to preparation XIII in 20 ml of acetonitrile is prepared and 0.75 ml (5.4 mM) of 4-methoxyphenyl isothiocyanate are added, and then 2 ml (14.4 mM) of triethylamine. The reaction mixture is kept under agitation for 2 hours at ambient temperature and then concentrated under reduced pressure. The residue is taken up into 50 ml of water and 100 ml of dichloromethane. The separated organic phase is dried over magnesium sulphate and then concentrated under reduced pressure. The residue is purified by chromatography on silica gel in eluting with the aid of a dichloromethane/methanol mixture (95/5; v/v). 370 mg of the product sought after are thus obtained as a white powder (yield=25%)

[0325] M PT.=88-90° C.

EXAMPLE 45

[0326] 5-hydroxy-5-methyl-1-[4-(4-morpholinyl)phenyl]-3-phenyl-2-thioxo-4-imidazolidinone

[0327] A solution of 1.7 g (4.3 mM) of the compound obtained according to Example 2 in 85 ml of dimethylsulphoxide is prepared and 8.5 ml of water are added. The reaction mixture is kept for 22 hours at 100° C., with introduction of compressed air. The solution is then cooled, poured onto 850 ml of water and the mixture obtained is extracted several times with ethyl acetate. The combined organic phases are washed with a solution of sodium chloride and then dried over magnesium sulphate and concentrated under reduced pressure. The residue is purified by chromatography on silica gel in eluting with the aid of a dichloromethane/ethyl ether mixture (90/10; v/v). The crystals obtained are washed with cyclohexane and then dried. 0.54 g of the product sought after are thus obtained as cream crystals (yield=54%).

[0328] M PT.=242-244° C.

EXAMPLE 46

[0329] 5-methyl-3-phenyl-1-[4-(4-thiomorpholinyl)phenyl]-2-thioxo-4-imidazolidinone, S-oxide

[0330] In performing analogously to Example 2, starting with the compound obtained according to preparation XV, the product sought after is obtained as white crystals (yield=55%).

[0331] M PT.=230° C.

EXAMPLE 47

[0332] 3-(3,4-dimethoxyphenyl)-5,5-dimethyl-1-[4-(4-morpholinyl)phenyl]-2-thioxo-4-imidazolidinone

[0333] In performing analogously to Example 39, starting with 3,4-dimethoxyphenyl isothiocyanate, the product sought after is obtained as white crystals (yield=7%).

[0334] M PT.=180° C.

EXAMPLE 48

[0335] 5-hydroxy-3-(4-methoxy-2-methylphenyl)-5-methyl-1-[4-(4-morpholinyl)-phenyl]-2-thioxo-4-imidazolidinone

[0336] 1 g (2.67 mM) of the amino acid obtained according to preparation II are mixed with 0.83 ml (5.34 mM) of 4-methoxy-2-methylphenyl isothiocyanate and 1.1 ml of triethylamine in 30 ml of dichloromethane and 30 ml of methanol are added. The reaction mixture is agitated for 24 hours at ambient temperature and then concentrated under reduced pressure. The residue is purified by chromatography on silica gel in eluting with the, aid off a dichloromethane/ethyl ether mixture (80/20; v/v). 0.23 g of the product sought are thus obtained after as a white powder (yield=21%).

[0337] M PT.=205° C.

EXAMPLE 49

[0338] 1-[4-(4-morpholinyl)phenyl]-3-phenyl-2-thioxo-4-imidazolidinone

[0339] 8 g of the acid obtained according to preparation XVI, 8 ml (68 mM) of phenyl isothiocyanate and 19 ml of triethylamine are mixed in 100 ml of acetonitrile and the mixture is agitated for 16 hours at ambient temperature. The reaction medium is then concentrated under reduced pressure and the residue is purified by chromatography on silica gel in eluting with a toluene/ethyl acetate mixture (60/40; v/v). 250 mg of the product sought after are thus obtained as beige crystals (yield=2%).

[0340] M PT.=250° C.

EXAMPLE 50

[0341] 3-[4-(4-morpholinyl)phenyl]-5-methyl-1-phenyl-2-thioxo-4-imidazolidinone

[0342] In performing analogously to Example 1, starting with the ethyl ester of N-phenylalanine and 4-(4-morpholinyl)phenyl isothiocyanate, the product sought after is obtained as a white powder (yield=64%).

[0343] M PT.=201 C

[0344] The chemical structures of the compounds according to the invention described above are summarised in Table I.

[0345] The other novel compounds, intermediates or compounds according to the invention, which are obtained according to methods analogous to those described above are grouped in the following Tables in which the chemical structure, certain physical characteristics, the yield of the reaction (noted as <<yld>>) and the preparation method, can be found. The melting point (M PT) is expressed in ° C.

[0346] Table III groups other examples of compounds according to the invention, which are in general obtained according to methods analogous to those described above.

[0347] In the case of salified compounds, HCl signifies hydrochloride, HBr signifies hydrobromide, Sulph signifies sulphate, Ms signifies methanesulphonate, Tfa signifies trifluoroacetate.

[0348] The compounds appearing in these Tables are obtained by means of methods analogous to those of the Preparations or Examples described above (method A is analogous to Example 7, method E is analogous to Example 1) or according to the methods described below (method M with microwaves, method F by fusion without solvent, method S with in situ generation of the isothiocyanate and method P of preparation of an amino ester).

[0349] Methods of obtaining intermediates or compounds of formula I:

[0350] Method M: (General Method)

[0351] 1 mmole of ester of formula (IIa) and 1.2 mmole of isothiocyanate R2—NCS (III) are placed in a PTFE reactor, and 2 drops of acetic acid are added. The reactor is then placed in a domestic microwave oven and is irradiated for 2 to 10 minutes (e.g. 2 minutes when R3=CH3 and R4═H, and 10 minutes when R3=R4=CH3), under a power of 700 to 900 W. After irradiation, the reactor is cooled and the reaction mixture is taken up with about 20 ml of ethyl ether. If the product sought after crystallises, the mixture is filtered and the compound sought after is isolated. If the product sought after does not crystallise, or is obtained impure, a purification by chromatography on silica gel is effected so as to obtain the pure product. The yields are indicated in the recapitulative Table of the compounds according to the invention.

[0352] Method F (Example 62):

[0353] The compound obtained according to preparation XXII (0.5 g; 1.71 mM) is mixed well with 0.35 g (2.05 mM) of 2,5-difluorophenyl isothiocyanate. After adding 5 drops of acetic acid, the reaction mixture is brought to a temperature of 120° C. (oil bath) for 1 hour 30 minutes. The product of the reaction is purified directly by chromatography on silica gel in eluting With the aid of a dichloromethane/ethyl acetate mixture (97/3; v/v). After crystallisation in isopropyl ether, the product sought after is obtained as a white solid (yield: 80%).

[0354] M PT.=148° C.

[0355] Method P (Preparation LXIII):

[0356] A solution of 0.3 g (1.27 mM) of 2,6-dimethyl-4-(4-morpholinyl)nitrobenzene in 15 ml of ethanol is prepared in a Parr flask. 0.217 g (1.27 mM) of sodium sulphate, 0.56 ml (1.27 mM) of ethyl pyruvate are added successively and under a nitrogen atmosphere. 30 mg of 10% palladium on carbon are finally added. The mixture obtained is hydrogenated under agitation and under a pressure of 3,400 hPa at ambient temperature for 5 hours. The reaction mixture is then filtered and the filtrate is concentrated under reduced pressure. The residue from evaporation is purified by chromatography on silica gel in eluting with the aid of a hexane/ethyl acetate mixture (80/20; v/v). The product sought after is obtained as a yellow oil (yield: 57%).

[0357] Method S (Example 303):

[0358] A solution of 1 g (5.6 mM) of thiocarbonyldiimidazole in 20 ml of dichloromethane is prepared and a solution of 1 g (5.6 mM) of 4-(4-morpholinyl)aniline in 10 ml of dichloromethane is added dropwise. The reaction mixture is then agitated for 1 hour at ambient temperature. 1.09 g (5.6 mM) of N-(4-methoxyphenyl)alanine in 10 ml of dichloromethane, then 0.78 ml (5.6 mM) of triethylamine, are added. The reaction mixture is agitated for 4 hours and then concentrated under reduced pressure. The residue from evaporation is purified by chromatography on silica gel in eluting with the aid of a dichloromethane/ethyl acetate mixture (90/10; v/v). The product sought after is obtained as white crystals (yield: 54%).

[0359] M PT.=202° C.

TABLE I
27
EX	R1	R2	R3	R4
1	28	29	CH3	H
2	30	31	CH3	H
3*	32	33	CH3	H
4	34	35	CH3	H
5	36	37	CH3	H
6	38	39	CH3	H
7	40	41	CH3	H
8	42	43	CH3	H
9	44	45	CH3	H
10	46	47	CH3	H
11	48	49	CH3	H
12	50	51	CH3	H
13	52	53	CH3	H
14	54	55	CH3	H
15	56	57	CH3	H
16	58	59	CH3	H
17	60	61	CH3	H
18	62	63	CH3	H
19	64	65	CH3	H
20	66	67	CH3	H
21	68	69	CH3	H
22	70	71	CH3	H
23	72	73	CH3	H
24	74	75	CH3	H
25	76	77	CH3	H
26	78	79	CH3	H
27	80	81	CH3	H
28	82	83	CH3	H
29	84	—C2H5	CH3	H
30	85	—CH2—CH═CH2	CH3	H
31	86	87	CH3	H
32	88	89	CH3	H
33	90	91	CH3	H
34	92	93	CH3	H
35	94	95	CH3	H
36	96	97	CH3	H
37	98	99	CH3	H
38	100	101	CH3	H
39	102	103	CH3	CH3
40	104	105	CH3	CH3
41	106	107	CH3	CH3
42	108	109	CH3	CH3
43	110	111	CH3	CH3
44	112	113	CH3	H
45	114	115	CH3	OH
46	116	117	CH3	H
47	118	119	CH3	CH3
48	120	121	CH3	OH
49	122	123	H	H
50	124	125	CH3	H
*: hydrochloride of Example 2

[0360]

TABLE II
Preparation		M PT		Yld	Method
No.	Structure	° C.	Appearance	%	(*)
XVII	126	107	Solid yellow	66	I
XVIII	127	98	Beige powder	67	I
XIX	128	123	Beige solid	53	I
XX	129	98	Yellow powder	89	XI
XXI	130	NMR	Violet oil	97	XII
XXII	131	NMR	light brown oil	64	I
XXIII	132	NMR	Yellow oil	88	I
XXIV	133	NMR	Yellow oil	91	I
XXV	134	81	Brown powder	100	IV
XXVI	135	>260	Yellow powder	30	IV
XXVII	136	NMR	Yellow oil	79	I
XXVIII	137	NMR	Brown oil	59	I
XXIX	138		Brown oil	52	I
XXX	139	60-70	gum	84	I
XXXI	140	NMR	Black oil	7	I
XXXII	141	NMR	Black oil	91	I
XXXV	142	61	White crystals	62	I
XXXVI	143	92-94	White crystals	62	I
XXXVII	144	90-92	White crystals	57	I
XXXVIII	145	58-60	Beige crystals	46	I
XXXIX	146	81	light brown solid	76	I
XL	147	60	Yellow solid	72	I
XLI	148	NMR	Yellow oil	63	I
XLIII	149	67	Violet solid	92	I
XLIV	150	NMR	Violet oil	90	XII
XLV	151	NMR	Violet oil	72	I
XLVI	152	NMR	Violet foam	100	XII
XLVII	153	NMR	Violet oil	92	I
XLVIII	154	146	Purplis pink powder	60	XII
IL	155	NMR	Violet oil	72	I
L	156	159	Brown solid	65	XII
LI	157	93	Beige solid	49	I
LII	158	NMR	Sticky solid	42	I
LIII	159	NMR	Sticky solid	42	I
LIV	160	NMR	Brown oil	8	IV
LV	161	160	Pinkish powder	71	XII
LVI	162	NMR	Clear oil	63	I
LVII	163	74	Violet powder	87	XII
LVIII	164	NMR	Oil	52	I
LIX	165	124	Brown solid	100	VII
LX	166	NMR	Beige solid	71	Prep I
LXI	167	NMR	Yellow oil	60	Prep I
LXII	168	NMR	Orange Paste	17	Prep I
LXIII	169	NMR	Yellow oil	57	P
LXIV	170	97	Brown powder	7	Prep I
LXV	171	NMR	Orange oil	66	Prep I
LXVI	172	NMR	Pink gum	40	Prep I
LXVII	173	NMR	Orange oil	83	Prep I
LXVIII	174	NMR	Black oil	66	Prep I
LXIX	175	NMR	Brown Oil	61	P
LXX	176	NMR	Yellow solid	75	P
LXXI	177	170	Yellow solid	99	Prep XI
LXXII	178	135	Yellow solid	92	Prep XI
LXXIII	179	NMR	White crystals	30	Prep IV
LXXIV	180	260	Beige powder	90	Prep IV
LXXV	181	196	Yellow powder	76	Prep IV
LXXVI	182	224	Brown crystals	78	Prep IV
LXXVII	183	NMR	Yellow crystals	47	Prep IV
LXXVIII	184		Not isolated		Prep IV
(*) Method used by analogy to that described in the preparation the number of which is indicated

[0361]

TABLE III
					M PT	Appear-	Yld
Ex	R1	R2	R3	R4	° C.	ance	%	Method
51	185	186	CH2CH3	H	164	White solid	27	F
52	187	188	(CH2)2CH3	H	136	Pinkish powder	23	E
53	189	190	CH3	H	218-220	Greyish powder	75	F
54	191	192	CH2CH3	H	188-190	White powder	67	F
55	193	194	(CH2)2CH3	OH	264	Greyish powder	46	F
56	195	196	CH2Ch3	H	222	Greyish powder	13	F
57	197	198	CH2CH3	H	128	Yellow- ish solid	63	F
58	199	200	CH3	H	171	White solid	13	E
59	201	202	CH2CH3	H	138	White powder	52	E
60	203	204	(CH2)2CH3	H	120	White solid	20	F
61	205	206	CH3	CH3	158	White solid	60	F
62	207	208	CH3	H	148	White solid	80	F
63	209	210	CH2CH3	H	131	White powder	43	E
64	211	212	(CH2)2CH3	H	148	white solid	51	F
65	213	214	CH2CH3	H	109	Yellow powder	86	F
66	215	216	(CH2)2CH3	H	135-150	Pale yellow solid	56	F
67	217	218	CH3	H	122	White solid	64	F
68	219	220	CH2CH3	H	85-90	Yellow foam	65	F
69	221	222	(CH2)2CH3	H	150	Pale yellow solid	49	F
70	223	224	CH3	H	144	White solid	89	F
71	225	226	CH2CH3	H	126	White powder	66	F
72	227	228	(CH2)2CH3	H	135	Pale yellow solid	25	E
73	229	230	CH2CH3	H	147	White powder	92	F
74	231	232	(CH2)2CH3	H	138	light beige solid	57	F
75	233	234	CH3	H	131	White solid	89	F
76	235	236	CH2CH3	H	138	White powder	78	F
77	237	238	(CH2)2CH3	H	107	Pink solid	30	F
78	239	240	CH3	CH3	118	Pink foam	91	F
79	241	242	CH3	H	190	Beige solid	59	F
80	243	244	CH2CH3	H	198	Cream solid	36	F
81	245	246	(CH2)2CH3	H	110-145	Yellow glassy solid	30	F
82	247	248	CH3	H	200-202	White powder	86	F
83	249	250	CH2CH3	H	169-171	White powder	86	F
84	251	252	(CH2)2CH3	H	138-140	White powder	59	F
85	253	254	CH3	H	158-175	Pale yellow powder	67	F
86	255	256	CH2CH3	H	230-232	light beige powder	71	F
87	257	258	(CH2)2CH3	H	288-230	Pale yellow powder	58	F
88	259	260	CH3	CH3	250	White solid	38	F
89	261	262	CH3	H	173	White powder	75	M
90	263	264	C2H5	H	194	White powder	47	M
91	265	266	C3H7	H	80-90	White foam	66	M
92	267	268	CH3	H	70	White powder	65	M
93	269	270	C2H5	H	97	Beige crystals	30	M
94	271	272	C3H7	H	103	Beige crystals	54	M
95	273	274	CH3	H	90-100	White foam	70	M
96	275	276	C2H5	H	98	White powder	52	M
97	277	278	C3H7	H	161	White powder	38	M
98	279	280	CH3	H	60	White powder	17	M
99	281	282	C2H5	H	60-70	Beige powder	51	M
100	283	284	C3H7	H	99	White powder	47	M
101	285	286	CH3	CH3	H 60	White powder	67	M
102	287	288	C2H5	H	80-90	White powder	38	M
103	289	290	C3H7	H	100	Beige powder	61	M
104	291	292	CH3	H	90	White powder	57	M
105	293	294	C2H5	H	80-90	Beige powder	29	M
106	295	296	C3H7	H	149	White powder	54	M
107	297	298	CH3	H	60	White powder	69	M
108	299	300	C2H5	H	60	White powder	41	M
109	301	CH3	CH	H163	Beige powder	64	M
110	302	303	CH3	H	152	Brown powder	16	M
111	304	305	CH3	H	105	White foam	77	M
112	306	307	C2H5	H	104	Beige powder	11	M
113	308	309	C3H7	H	80	Beige crystals	37	M
114	310	311	CH3	H	130-140	White powder	44	M
115	312	313	C2H5	H	120-130	White powder	16	M
116	314	315	C3H7	H	154	White powder	11	M
117	316	317	CH3	H	130	White powder	21	M
118	318	319	CH3	H	192-194	White crystals	70	F
119	320	321	C2H5	H	146-148	White crystals	66	F
120	322	323	C3H7	H	120-122	White crystals	55	F
121	324	325	CH3	H	168-170	White crystals	46	F
122	326	327	C2H5	H	146-148	White crystals	53	F
123	328	329	C3H7	H	116-118	White crystals	51	F
124	330	331	CH3	H	168-170	White crystals	46	F
125	332	333	C1H5	H	146-148	White crystals	52	F
126	334	335	C3H7	H	110-112	Pale yellow crystals	57	F
127	336	337	CH3	H	162-164	White crystals	44	F
128	338	339	C2H5	H	110-112	Beige crystals	46	F
129	340	341	C3H7	H	112-114	White crystals	23	F
130	342	343	CH3	H	166-168	White crystals	37	F
131	344	345	C2H5	H	140-142	White crystals	63	F
132	346	347	C3H7	H	130-132	Pale yellow crystals	40	F
133	348	349	CH3	H	182-184	White crystals	81	F
134	350	351	C2H5	H	130-132	White crystals	66	F
135	352	353	C3H7	H	90-92	White crystals	44	F
136	354	355	CH3	H	160-162	White crystals	78	F
137	356	357	C2H5	H	164-166	White crystals	57	F
138	358	359	C3H7	H	134-136	White crystals	49	F
139	360	361	CH3	H	134-136	Beige crystals	20	F
140	362	363	C2H5	H	118-120	Beige crystals	16	F
141	364	365	C3H7	H	140-142	Beige crystals	5	F
142	366	367	CH3	H	104-106	White crystals	50	F
143	368	369	C2H5	H	138-140	White crystals	50 F
144	370	371	C3H7	H	70-72	Beige crystals	44	F
145	372	373	CH3	H	168-170	White crystals	41	F
146	374	375	C2H5	H	134-136	White crystals	55	F
147	376	377	C3H7	H	134-136	Yellow crystals	34	F
148	378	379	CH3	H	232-234	Pink crystals	16	F
149	380	381	C2H5	H	102-104	Beige crystals	11	E
150	382	383	C2H5	199	Beige solid	50	F
151	384	385	C3H7	H	52	Amor- phous solid	41	F
152	386	387	C2H5	H	170-190	Beige solid	41	F
153	388	389	C3H7	H	48	Amor- phous solid	44	F
154	390	391	C2H5	H	174	Beige solid	41	F
155	392	393	C3H7	H	47	Amor- phous solid	48	F
156	394	395	C2H5	H	188	Beige solid	48	F
157	396	397	C3H7	H	55	Amor- phous solid	72	F
158	398	399	C3H7	H	45	Amor- phous solid	25	F
159	400	401	C2H5	H	126-142	Beige solid	39	F
160	402	403	C3H7	H	53	Amor- phous solid	54	F
161	404	405	C3H7	H	59	Amor- phous solid	32	F
162	406	407	C2H5	H	110-128	White solid	37	F
163	408	409	C3H7	H	60	Amor- phous solid	58	F
164	410	411	CH2CH3	H	136-145	Brown solid	9	F
165	412	413	C2CH5	H	155	White solid	81	F
166	414	415	C3CH7	H	157	White solid	90	F
167	416	417	CH3	H	176	Beige solid	76	F
168	418	419	C2H5	H	146	Beige solid	66	F
169	420	421	C3H7	H	140	Beige solid	61	F
170	422	423	CH3	H	125	Beige solid	58	F
171	424	425	C2H5	H	167	light brown solid 75	F
172	426	427	C3H7	H	157	Pale yellow solid	25	F
173	428	429	CH3	H	176	Beige solid	72	F
174	430	431	C2H5	H	141	Yellow solid	42	F
175	432	433	C3H7	H	167	Pale yellow solid	71	F
176	434	435	CH3	H	192	Pale yellow solid	90	F
177	436	437	C2H5	H	114	Pale yellow solid	65	F
178	438	439	C3H7	H	107	White solid	50	F
179	440	441	CH3	H	164	Pale yellow solid	76	F
180	442	443	C2H5	H	188	Pale yellow solid	88	F
181	444	445	C3H7	H	170	White solid	82	F
182	446	447	CH3	H	98	Orange solid	98	F
183	448	449	C2H5	H	146	light brown solid	81	F
184	450	451	C3H7	H	144	Beige solid	12	F
185	452	453	C3H7	H	250	White solid	22	F
186	454	455	CH3	H	170	light brown solid	61	F
187	456	457	C2H5	H	147	Beige brown solid	51	F
188	458	459	C3H7	H	167	White solid	87	F
189	460	461	C2H5	H	171	White powder	43	F
190	462	463	C2H5	H	147	White powder	54	F
191	464	465	C2H5	H	110-124	Glassy brown solid	60	F
192	466	467	C2H5	H	188	Pink powder	85	F
193	468	469	C2H5	H	98-110	Green- ish powder	10	F
194	470	471	C2H5	H	125	Beige solid	49	F
195	472	473	C3H7	H	48	Amor- phous solid	52	F
196	474	475	C2H5	H	120	Glassy yellow- ish solid	57	F
197	476	477	C2H5	H	188	White powder	67	F
198	478	479	C2H5	H	128	Yellow powder	51	F
199	480	481	C2H5	H	190-192	Green- ish powder	7	F
200	482	483	C2H5	H	220-221	Beige crystals	80	F
201	484	485	C2H5	H	202-203	Beige powder	66	F
202	486	487	CH2CH3	H	105	White powder	56	F
203	488	489	CH2CH2CH3	H	166	White solid	81	F
204	490	491	CH2CH2CH3	H	174	White solid	68	F
205	492	493	CH2CH2CH3	H	105	Pale yellow powder	92	F
206	494	495	CH3	CH3	228	Beige crystals	62	F
207	496	497	CH2CH3	H	141-142	Beige pinkish powder	57	F
208	498	499	CH2CH2CH3	H	148	Beige pinkish powder	79	F
Exam-						Yld
ple	R1	R2	R3	R4	M PT	%	Method
209	500	501	CH3	H	140	10	A
210	502	503	CH3	H	213	63	E
211	504	505	CH2	192	13	E
212	506	507	CH3	HO	148	30	Ex 45
213	508	509	CH3	H	234	100	HBr SALT
214	510	511	CH3	H	130	92	Ms SALT
215	512	513	CH3	H	160	50	Sulph SALT
216	514	515	CH3	H	177	94	HCl SALT
217	516	517	CH3	H	196	72	F
218	518	519	CH3	H	192	81	HCl SALT
219	520	521	CH3	H	252	56	E
220	522	523	CH3	H	130	34	E
221	524	525	CH3	H	270	12	A
222	526	527	CH3	H	210	43	E
223	528	529	CH3	H	213	38	E
224	530	531	CH3	H	224	80	E
225	532	533	CH3	H	202	78	E
226	534	535	CH3	H		22	E
227	536	537	CH3	H	112	30	E
228	538	539	CH3	H	220	60	Ex 16 +RSO2Cl
229	540	541	CH3	H	110	55	E
230	542	543	CH3	H	136	25	E
231	544	545	CH3	H	260	60	Ex 16 +RSO2Cl
232	546	547	CH3	H	150	39	E
233	548	549	CH3	H	178	63	E
234	550	551	CH3	H	112	40	E
235	552	553	CH3	H	167	23	E
236	554	555	CH3	H	164	38	E
237	556	557	CH3	H	206	80	E
238	558	559	CH3	H	140	42	E
239	560	561	CH3	H	90	25	A
240	562	563	CH3	H	147	62	E
241	564	565	CH3	H	177	86	E
242	566	567	CH3	H	240	35	A
243	568	569	CH3	H	203	20	A
244	570	571	CH3	H	93	92	E
245	572	573	CH3	H	223	75	2TFa SALT
246	574	575	CH3	H	NMR	68	E
247	576	577	CH3	H	NMR	67	A
248	578	579	CH3	H	260	30	A
249	580	581	CH3	H	148	23	A
250	582	583	CH3	H	154	40	A
251	584	585	CH3	H	158	30	A
252	586	587	CH3	H	136	15	S
253	588	589	CH3	H	148	40	A
254	590	591	CH3	H	156	16	E
255	592	593	CH3	H	170	47	E
256	594	595	CH3	H		53	A
257	596	597	CH3	H		51	S
258	598	599	CH3	H		30	S
259	600	601	CH3	H	134	90	M
260	602	603	CH3	H	120	68	M
261	604	605	CH3	H	163	77	A
262	606	607	CH3	H	161	49	M
263	608	609	CH3	H		74	M
264	610	611	CH3	H		72	M
265	612	613	CH3	H	110	73	M
266	614	615	CH3	H	91	68	M
267	616	617	CH3	H		70	S
268	618	619	CH3	H	104	52	2TFa SALT
269	620	621	CH3	H		24	A
270	622	623	CH3	CH3	216	57	E
271	624	625	CH3	CH3	200	77	E
272	626	627	CH3	H	190	77	M
273	628	629	CH3	H	208	94	M
274	630	631	CH3	H	244	84	M
275	632	633	CH3	H	200	80	A
276	634	635	CH3	H		50	S
277	636	637	CH3	H	123	25	S
278	638	639	CH3	H	161	58	M
279	640	641	CH3	H	140	80	M
280	642	643	CH3	H	193	78	M
281	644	645	CH3	H	172	92	M
282	646	647	C2H5	H	96	50	E
283	648	649	C2H5	H	194	57	E
284	650	651	CH3	H	70	61	E
285	652	653	CH3	H		92	E
286	654	655	CH3	H	84	83	M
287	656	657	CH3	H	254	88	M
288	658	659	CH3	H	148	83	M
289	660	661	CH3	H	154	80	E
290	662	663	CH3	H	183	46	E
291	664	665	CH3	H	90	69	E
292	666	667	CH3	H	140	18	E
293	668	669	CH3	H	92	57	M
294	670	671	CH3	H		12	S
295	672	673	CH3	H		15	S
296	674	675	CH3	H	211	73	A
297	676	677	CH3	H	140	44	A
298	678	679	CH3	H	260	86	E
299	680	681	CH3	H	242	80	E
300	682	683	CH3	H	105	71	M
301	684	685	CH3	H		90	A
302	686	687	CH3	H		68	E
303	688	689	CH3	H	203	54	S
304	690	691	CH3	H	180	73	2TFa SALT
305	692	693	CH3	H	190	75	M
306	694	695	CH3	H	144	22	A
307	696	697	CH3	H	120	94	2HCl SALT
308	698	699	CH3	H	90	64	M
309	700	701	CH3	H	180	29	A
310	702	703	CH3	H	173	12	E
311	704	705	CH3	H	183	71	M
312	706	707	CH3	H		58	M
313	708	709	CH3	H	190	21	M
314	710	711	CH3	H		32	A
315	712	713	CH3	H		76	A
316	714	715	CH3	H	208	72	E
317	716	717	CH3	H	214	58	E
318	718	719	CH3	H	170	68	M
319	720	721	CH3	H	95	62	M
320	722	723	CH3	H	195	75	M
321	724	725	CH3	H	174	22	S
322	726	727	CH3	H	145	50	A
323	728	729	CH3	H	220	56	E
324	730	731	CH3	H	88	23	M
325	732	733	CH3	H		6	E
326	734	735	CH3	CH3	188	63	M
327	736	737	CH3	CH3	183	66	M
328	738	739	CH3	CH3	290	32	M
329	740	741	HO	CH3	240	10	Ex 45
330	742	743	CH3	CH3	204	73	M
331	744	745	CH3	CH3	260	80	M
332	746	747	CH2	224	9	Ex 1 +dmso reflux +air 8h
333	748	749	CH3	H	180	44	M
334	750	751	CH3	H	168	83	M
335	752	753	CH3	CH3	178	40	M
336	754	755	CH3	H	191	74	M
337	756	757	CH3	CH3	170	51	M
338	758	759	CH3	H	140	82	M
339	760	761	CH3	H	206	61	M
340	762	763	CH3	H	221	80	M
341	764	765	CH3	CH3	170	14	A
342	766	767	CH3	CH3	260	13	S
343	768	769	CH3	H	158	59	M
344	770	771	C2H5	H	161	12	M
345	772	773	CH3	CH3	228	50	A
346	774	775	CH3	CH3	174	17	A
347	776	777	CH3	CH3	260	81	A
348	778	779	CH3	H	85	79	M
349	780	781	CH3	H	150	45	M
350	782	783	CH3	H	217	76	M
351	784	785	CH3	H	196	75	M
352	786	787	C3H7	H	90	79	M
353	788	789	C3H7	H	90	93	M
354	790	791	CH3	H	241	66	M
355	792	793	CH3	H	192	54	M
356	794	795	C3H7	H	60	52	M
357	796	797	C3H7	H	179	46	M
358	798	799	HO	CH3	100	44	Ex 45
359	800	801	CH3	CH3	144	12	S
360	802	803	C2H5	H	189	64	A
361	804	805	CH3	CH3	172	14	M
362	806	807	CH3	CH3	158	12	M
363	808	809	CH3	CH3	260	100	A
364	810	811	CH3	H	150	78	F
365	812	813	CH3	H	186	50	M
366	814	815	CH3	H	88	98	F
367	816	817	CH3	H	176	70	F
368	818	819	CH3	H	98	87	F
369	820	821	CH3	H	250	93	F
370	822	823	CH3	H	60	69	M
371	824	825	CH3	H	60	67	M
372	826	827	CH3	H	60	17	M
373	828	829	CH3	H	70	65	M
374	830	831	CH3	H	258	83	A
375	832	833	CH3	H	176	74	A
376	834	835	CH3	H	150	98	A
377	836	837	CH3	H	156	37	A
378	838	839	CH3	H	144	38	A
379	840	841	CH3	H		88	A
380	842	843	C2H5	H	182	71	F

[0362] The non-crystallised compounds appearing in the Tables above were characterised by their proton NMR spectrum, the values of which (chemical shift, form and intensity of signal), are given below:

[0363] Preparation XXI

[0364] 1 H NMR (DMSO d6, 300 MHz): 1.86 (m, 2H); 3.39 (m, 4H); 3.55 (m, 2H); 3.66 (m, 2H); 4.30 (s, 2H); 6.50 (m, 4H).

[0365] Preparation XXII

[0366] 1 H NMR (DMSO d6, 250 MHz): 1.15 (t, 3H); 1.32 (d, 3H); 1.86 (m, 2H); 3.41 (m, 4H); 3.55 (m, 2H); 3.67 (m, 2H); 3.91 (m, 1H); 4.06 (q, 2H); 5.16 (d, 1H); 6.47 (m, 2H); 6.56 (m, 2H).

[0367] Preparation XXIII

[0368] 1 H NMR (CDCl3, 250 MHz): 1.00 (t, 3H); 1.24 (t, 3H); 1.81 (m, 2H); 2.00 (m, 2H); 3.51 (m, 4H); 3.70 (m, 3H); 3.79 (m, 2H); 3.89 (m, 1H); 4.18 (q, 2H); 6.61 (m, 4H).

[0369] Preparation XXIV

[0370] 1 H NMR (DMSO d6, 300 MHz): 0.89 (t, 3H); 1.14 (t, 3H); 1.40 (m, 2H); 1.66 (m, 2H); 1.87 (m, 2H); 3.40 (m, 4H); 3.55 (m, 2H); 3.66 (m, 2H); 3.82 (m, 1H); 4.06 (q, 2H); 5.13 (d, 1H); 6.48 (m, 2H); 6.55 (m, 2H).

[0371] Preparation XXVII

[0372] 1 H NMR(CDCl3, 250 MHz): 1.22 (t, 3H); 1.45 (s, 6H); 2.00 (m, 2H); 3.53 (m, 4H); 3.68 (m, 3H); 3.80 (m, 2H); 4.15 (q, 2H); 6.58 (m, 2H); 6.70 (m, 2H).

[0373] Preparation XXVIII

[0374] 1 H NMR (CDCl3, 300 MHz): 1.00 (t, 3H); 1.24 (t, 3H); 1.80 (m, 2H); 2.61 (t, 2H); 2.68 (m, 4H); 3.07 (m, 4H); 3.66 (t, 2H); 3.92 (m, 2H); 4.17 (q, 2H); 6.60 (m, 2H); 6.82 (m, 2H).

[0375] Preparation XXXI

[0376] 1 H NMR (DMSO d6, 300 MHz): 0.94 (t, 3H); 1.14 (t, 3H); 1.48 (m, 2H); 1.73 (m, 4H); 2.59 (m, 2H); 3.24 (m, 1H); 3.50 (m, 1H); 3.80 (m, 1H); 4.40 (q, 2H); 4.60 (s, 1H); 5.37 (d, 1H); 6.49 (d, 2H); 6.71 (d, 2H).

[0377] Preparation XXXII

[0378] 1 H NMR (DMSO d6, 300 MHz): 0.89 (t, 3H); 1.16 (t, 3H); 1.43 (m, 4H); 1.69 (m, 4H); 2.54 (m, 2H); 3.24 (m, 2H); 3.52 (m, 1H); 3.84 (m, 1H); 4.37 (q, 2H); 4.60 (s, 1H); 5.37 (d, 1H); 6.46 (d, 2H); 6.71 (d, 2H).

[0379] Preparation XLI

[0380] 1 H NMR (DMSO d6, 250 MHz) 0.89 (t, 3H); 1.17 (t,3H); 1.39 (m, 2H); 1.59 (m, 6H); 3.00 (t, 4H); 3.82 (m, 5H); 4.06 (q, 2H); 7.40 (d, 1H); 6.47 (d, 2H); 6.74 (d,2H).

[0381] Preparation XLIV

[0382] 1 H NMR (CDCl3, 300 MHz): 2.67 (m, 4H); 3.27 (s, 2H); 3.77 (m, 4H); 6.54 (d, 1H); 6.98 (dd, 1H); 7.78 (d, 1H).

[0383] Preparation XLV

[0384] 1 H NMR (CDCl3, 250 MHz): 1.01 (t, 3H); 1.25 (t, 3H); 1.82 (m, 2H); 2.68 (m, 4H); 3.76 (m, 5H); 3.86 (m, 1H); 4.18 (m, 2H); 6.55 (d, 1H); 6.95 (dd, 1H); 7.73 (d, 1H).

[0385] Preparation XLVI

[0386] 1 H NMR (CDCl3, 300 MHz): 1.23 (m, 9H); 1.96 (m, 2H); 3.46 (m, 2H); 3.60 (m, 2H); 3.76 (m, 4H); 6.42 (d, 1H); 6.97 (dd, 1H); 7.73 (d,2H).

[0387] Preparation XLVII

[0388] 1 H NMR (CDCl3, 300 MHz): 1.01 (t, 3H); 1.22 (s, 9H); 1.27 (t, 3H); 1.80 (m, 2H); 1.96 (m, 2H); 3.45 (m, 2H); 3.60 (m, 3H); 3.80 (m, 4H); 4.17 (m, 2H); 6.44 (d, 1H); 6.95 (dd, 1H); 7.68 (d, 1H).

[0389] Preparation XLVIII

[0390] 1 H NMR (CDCl3, 300 MHz): 1.00 (t, 3H); 1.25 (t, 3H); 1.81 to 1.95 (m, 6H); 2.91 (m, 2H); 3.43 (m, 1H); 3.73 (m, 1H); 3.88 (m, 1H); 4.16 (m, 4H); 6.64 (d, 1H); 6.96 (dd, 1H); 7.45 to 7.59 (m, 3H); 7.74 (d, 1H); 7.96 (m, 2H).

[0391] Preparation LIV

[0392] 1 H NMR (CDCl3, 300 MHz): 3.89 (s, 3H); 6.17 (d, 1H); 7.14 (d, 1H).

[0393] Preparation LVI

[0394] 1 H NMR (CDCl3, 300 MHz): 1.0 (t, 3H); 1.24 (t, 3H); 1.82 (m, 2H); 2.85 (s, 6H). 3.07 (m, 4H); 3.39 (m, 4H); 3.94 (m, 2H); 4.17 (q, 2H); 6.60 (d, 2H); 6.82 (d, 2H).

[0395] Preparation LVIII

[0396] 1 H NMR (CDCl3, 300 MHz): 1.0 (t, 3H); 1.24 (t, 3H); 1.73 to 2.01 (m, 6H); 2.40 (m, 1H); 2.67 (m, 2H); 3.42 (m, 2H); 3.70 (s, 3H); 3.93 (m, 2H); 4.17 (q, 2H); 6.59 (d, 2H); 6.85 (m, 2H).

[0397] Preparation LX

[0398] 1 H NMR (CDCl3, 300 MHz): 1.24 (t, 3H); 1.44 (d, 3H); 1.52 (m, 2H); 1.70 (m, 4H); 2.98 (m, 4H); 4.05 (q, 1H); 4.15 (q, 2H); 6.58 (d, 2H); 6.86 (d, 2H).

[0399] Preparation LXI

[0400] 1 H NMR (CDCl3, 300 MHz): 1.20 (t, 3H); 1.32 (d, 3H); 2.22 (s, 3H); 2.26 (s, 3H); 3.82 (m, 2H); 3.96 (m, 2H); 3.85 (m, 4H); 4.11 (q, 2H); 4.54 (q, 1H) 6.71 (d, 2H).

[0401] Preparation LXII

[0402] 1 H NMR (CDCl3, 300 MHz): 1.27 (t, 3H); 1.45 (d, 3H); 2.56 (t, 4H); 3.42 (t, 4H); 4.08 (q, 1H); 4.20 (q, 2H); 6.62 (d, 2H); 6.89 (d, 2H).

[0403] Preparation LXIII

[0404] 1 H NMR (CDCl3, 300 MHz) 1.23 (d, 6H); 1.24 (t, 3H); 1.44 (d, 3H); 2.32 (d, 2H); 3.25 (d, 2H); 3.82 (m, 2H); 4.08 (q, 1H); 4.16 (q, 2H); 6.61 (d, 2H) 6.85 (d, 2H).

[0405] Preparation LXV

[0406] 1 H NMR (CDCl3, 300 MHz): 1.01 (t, 3H); 1.28 (t, 3H); 1.81 (m, 2H); 3.98 (m, 1H); 4.21 (q, 2H); 6.37 (m, 3H); 7.08 (q, 1H).

[0407] Preparation LXVI

[0408] 1 H NMR (CDCl3, 300 MHz): 1.26 (t, 3H); 1.46 (d, 3H); 3.13 (m, 4H); 3.62 (m, 4H); 4.07 (q, 1H); 4.21 (q, 2H); 6.59 (d, 2H); 6.82 (d, 2H).

[0409] Preparation LXVII

[0410] 1 H NMR (CDCl3, 300 MHz) 1.17 (t, 3H); 1.30 (d, 6H); 1.49 (s, 6H); 2.34 (m, 2H); 3.28 (d, 2H); 3.80 (m, 2H); 4.14 (q, 2H); 6.64 (d, 2H); 6.77 (d, 2H).

[0411] Preparation LXVIII

[0412] 1 H NMR (CDCl3, 250 MHz): 1.28 (t, 3H); 1.44 (d, 3H); 1.53 (m, 4H); 1.81 (m, 4H); 3.41 (m, 4H); 4.17 (m, 3H); 6.53 (m, 4H).

[0413] Preparation LXIX

[0414] 1 H NMR (DMSO d6, 250 MHz): 1.13 (t, 3H); 1.32 (d, 3H); 1.93 (m, 2H); 3.28 (t, 4H); 3.45 (t, 4H); 3.77 (m, 2H); 3.90 (m, 1H); 4.05 (q, 2H); 5.15 (d, 1H) 6.52 (m, 6H); 7.43 (m, 1H); 8.03 (m, 1H).

[0415] Preparation LXX

[0416] 1 H NMR (CDCl3, 250 MHz) 1.23 (t, 3H); 1.43 (d, 3H); 2.06 (q, 2H); 3.43 (t, 2H); 3.56 (t, 2H); 3.67 (t, 2H); 3.98 (m, 3H); 4.16 (q, 2H); 6.44 (t, 1H); 6.62 (q, 4H); 8.17 (d, 2H).

[0417] Preparation LXXIII

[0418] 1 H NMR (CDCl3, 250 MHz): 6.56 (m, 1H); 7.10 (d, 1H); 7.28 (m, 1H); 7.38 (d, 1H); 7.55 (d, 1H); 8.27 (s, 1H).

[0419] Preparation LXXVII

[0420] 1 H NMR (DMSO d6, 250 MHz): 3.11 (s, 3H); 3.57 (s, 2H); 7.02 (d, 1H); 7.37 (m, 2H).

EXAMPLE 226

[0421] 1 H NMR(CDCl3, 300 MHz): 1.51 (d, 3H); 3.22 (s, 4H); 3.86 (s, 4H); 4.58 (q, 1H); 5.41 (s, 1H); 6.90 (m, 4H); 7.32 (m, 4H).

EXAMPLE 246

[0422] 1 H NMR (CDCl3, 250 MHz): 1.39 (d, 3H); 3.21 (q, 4H); 3.37 (s, 3H); 3.53 (m, 2H); 3.68 (m, 2H); 3.84 (m, 6H); 4.12 (m, 2H); 4.37 (q, 1H); 6.95 (d, 2H); 7.21 (d, 2H).

EXAMPLE 247

[0423] 1 H NMR (CDCl3, 250 MHz): 1.32 (d, 3H); 2.09 (m, 2H); 2.72 (t, 2H); 3.21 (q, 2H); 3.86 (m, 4H); 3.97 (t, 2H); 4.23 (q, 1H) 6.94 (m, 2H); 7.21 (m, 7H).

EXAMPLE 256

[0424] 1 H NMR (CDCl3, 250 MHz): 1.38 (d, 3H); 3.20 (q, 4H); 3.84 (q, 4H); 4.36 (q, 1H); 5.01 (q, 2H); 5.93 (s, 2H); 6.75 (d, 1H); 6.92 (m,2H); 7.05 (m, 2H); 7.22 (m, 2H).

EXAMPLE 257

[0425] 1 H NMR (CDCl3, 250 MHz): 1.41 (d, 3H); 1.94 (m, 2H); 2.73 (s, 1H); 3.22 (m, 2H); 3.62 (s, 2H); 3.85 (m, 4H); 4.09 (t, 2H); 4.40 (q, 1H); 6.95 (m, 2H) 7.24 (m, 2H).

EXAMPLE 258

[0426] 1 H NMR (CDCl3, 250 MHz): 0.93 (m, 3H); 1.37 (m, 2H); 1.51 (d, 3H); 1.65 (m, 2H); 2.66 (m, 2H); 3.22 (m, 4H); 3.85 (m, 4H); 4.58 (q, 1H); 6.96 (m, 2H) 7.28 (m, 6H).

EXAMPLE 263

[0427] 1 H NMR (CDCl3, 300 MHz): 1.40 (d, 3H); 2.79 (2t, 2H); 3.21 (t, 4H); 3.69 (s, 3H); 3.86 (t, 4H); 4.21 (t, 2H); 4.38 (q, 1H); 6.95 (d, 2H); 7.23 (d, 2H).

EXAMPLE 264

[0428] 1 H NMR (CDCl3, 300 MHz) 1.39 (d, 3H) 2.02 (m, 2H); 3.21 (m, 4H); 3.32 (s, 3H); 3.48 (t, 2H); 3.86 (m, 4H); 4.01 (t, 2H); 4.35 (q, 1H) 6.95 (d, 2H); 7.24 (d, 2H).

EXAMPLE 267

[0429] 1 H NMR (DMSO d6, 300 MHz): 1.33 (d, 3H); 2.58 (t, 2H); 2.86 (t, 2H); 3.16 (m, 2H); 3.44 (s, 1H); 3.74 (m, 2H); 4.97 (q, 1H); 7.03 (d, 2H); 7.27 (d, 2H); 7.36 (m, 4H)

EXAMPLE 269

[0430] 1 H NMR (CDCl3, 300 MHz): 1.40 (d, 3H); 1.61 (m, 6H); 3.22 (m, 4H); 3.51 (m, 1H); 3.82 (m, 2H); 3.86 (t, 4H); 4.06 (m, 2H); 4.23 (m, 1H); 4.39 (q, 1H); 4.74 (t, 1H) 6.96 (d, 2H); 7.24 (d, 2H).

EXAMPLE 276

[0431] 1 H NMR (CDCl3, 250 MHz): 1.54 (d, 3H); 2.92 (t, 2H); 3.22 (m, 4H); 3.88 (m, 6H); 4.58 (q, 1H); 6.97 (m, 2H); 7.31 (m, 6H).

EXAMPLE 285

[0432] 1 H NMR (CDCl3, 300 MHz): 1.44 (t, 3H); 3.21 (m, 4H); 3.79 (s, 3H); 3.86 (m, 4H); 4.48 (m, 4H); 4.48 (q, 1H); 4.69 (d, 2H); 6.94 (d, 2H); 7.26 (d, 2H).

EXAMPLE 294

[0433] 1 H NMR (CDCl3, 250 MHz): 1.30 (m, 2H); 1.37 (d, 3H); 1.75 (m, 2H); 1.81 (m, 2H); 3.21 (m, 4H); 3.66 (t, 2H); 3.85 (m, 4H); 3.92 (m, 2H); 4.36 (q, 1H); 6.96 (d, 2H); 7.24 (d, 2H).

EXAMPLE 295

[0434] 1 H NMR (CDCl3, 300 MHz): 1.35 (d, 3H); 1.45 (m, 4H); 1.61 (m, 2H); 1.80 (m, 2H); 3.22 (q, 4H); 3.65 (t, 2H); 3.85 (m, 2H); 3.90 (m, 2H); 4.35 (q, 1H); 6.97 (m, 2H); 7.24 (m, 2H).

EXAMPLE 301

[0435] 1 H NMR (CDCl3, 300 MHz) 1.27 (m, 3H); 1.41 (m, 3H); 1.69 (d, 3H); 3.21 (m, 4H); 3.86 (m, 4H); 4.23 (m, 2H); 4.38 (t, 1H); 5.50 (m, 1H); 6.95 (d, 2H); 7.25 (m, 2H).

EXAMPLE 302

[0436] 1 H NMR (CDCl3, 300 MHz): 1.41 (m, 12H); 1.90 (t, 2H); 3.20 (m, 4H); 3.86 (m, 4H); 3.99 (t, 2H); 4.38 (q, 1H); 5.1 (m, 1H); 6.94 (d, 2H); 7.23 (d, 2H).

EXAMPLE 312

[0437] 1 H NMR (CDCl3, 250 MHz): 0.97 (t, 3H); 1.39 (m, 5H); 1.70 (m, 2H); 3.21 (m, 4H); 3.88 (m, 6H); 4.35 (q, 1H); 6.95 (d, 2H); 7.24 (d, 2H).

EXAMPLE 314

[0438] 1 H NMR (CDCl3, 250 MHz): 1.39 (d, 3H); 1.92 (m, 2H); 2.43 (m, 6H); 3.21 (m, 4H); 3.71 (t, 4H); 3.86 (q, 4H); 4.36 (q, 1H); 6.95 (m, 2H); 7.24 (m, 2H).

EXAMPLE 315

[0439] 1 H NMR (CDCl3, 300 MHz): 0.98 (d, 6H); 1.38 (d, 3H); 1.61 (m, 2H); 3.21 (m, 4H); 3.88 (m, 6H); 4.34 (q, 1H); 6.94 (d, 2H); 7.24 (m, 2H).

EXAMPLE 325

[0440] 1 H NMR (CDCl3, 300 MHz) 1.54 (d, 3H); 3.23 (t, 4H); 3.51 (s, 3H); 3.86 (m, 4H); 4.6 (d, 2H); 6.59 (d, 1H); 6.98 (m, 2H); 7.21 (m, 1H); 7.32 (m, 4H).

EXAMPLE 379

[0441] 1 H NMR (CDCl3, 300 MHz): 1.53 (d, 3H); 1.69 (m, 6H); 3.23 (m, 4H); 3.92 (s, 3H); 4.59 (q, 1H); 6.97 (d, 2H); 7.24 (d, 1H); 7.25 (m, 2H); 7.59 (m, 2H); 8.08 (m, 2H).

[0442] Compounds of formula I according to the invention were subjected to pharmacological tests in order to evaluate their potential to decrease the level of glycaemia in the blood.

[0443] Experimental Method

[0444] In vivo studies were made on male C57BL/KsJ-db/db mice, originating from CERI] (Route des Chênes Secs—BP 5—53940 Le Genest St Isle—France).

[0445] The animals were accommodated in cages equipped with a filter cover and have free access to an irradiated standard nourishment as well as to filtered drinking water. All the material used (cages, feeding bottles, pipettes and shavings) is sterilised by autoclave, irradiation or soaking in a disinfectant. The temperature of the room is kept at 23±2° C. The light and dark cycle is of 12 hours.

[0446] During the acclimatisation period, each animal is labelled with the aid of an electronic chip, the implantation of which is done under anaesthetic by inhalation of a CO2/O2 mixture.

[0447] Groups of 10 mice are made and the treatments start when the animals are 10 to 11 weeks old. The products are placed in suspension in gum arabic at 3% and are administered to the animals with the aid of a feeding cannula, for 10 days, at the rate of two administrations per day, as well as the morning of the eleventh day. The products are tested of doses of less than 200 mg/kg. The animals of the control group receive the administration vehicle only.

[0448] A blood sample is taken before treatment, and then three hours after the last administration of the product. The animals are anaesthetised by inhalation of a CO2/O2 mixture, the blood is taken from the retro-orbital sinus, collected in a dry tube and kept in the cold. The serum is prepared by centrifugation at 2,800 g (15 minutes, 4° C.) in the hour following the sampling. The samples are kept at −20° C. until the analysis.

[0449] The serum levels of glucose and triglycerides are determined with a Konelab 30 analyser, with the aid of Konelab kits. The animals the glycaemia of which before treatment was less than 3 g/l are systematically excluded from the study.

[0450] For each group, the average levels of glucose and triglycerides before and after treatment are calculated and the results are expressed in percentage variation of these averages with time.

[0451] The results expressed in percentage variation of the level of glycaemia and of the level of triglycerides show that the compounds of formula I according to the invention or their addition salts with a non-toxic acid, enable the level of glycaemia to drop to values of −73% and the level of triglycerides to values of −56%. It was also observed that the treatment with the compounds according to the invention were accompanied with a favourable modification of the lipid parameters.

[0452] The compounds according to the invention can be used as an active principle of a medicament which is intended for treating diabetes in mammals and, more particularly, in man. They can be used for fighting against hypertriglyceridaemiae and diseases caused by an excess of triglycerides in the blood, such as atherosclerosis, for example.

[0453] More generally, the compounds can be useful for the prevention or the treatment of diseases associated with a hyperglycaemia or a hypertriglyceridaemia, such as adult diabetes, hypertension, dyslipidaemiae, cardiovascular diseases, and obesity; they are also useful for the treatment of diseases caused by microvascular or macrovascular complications in the diabetic, notably of the renal system or the central nervous system, said complications being in general associated with the X metabolic syndrome. The compounds according to the invention are also useful for treating cerebral ischaemia or cerebral vascular accident.

[0454] Pharmaceutical compositions incorporating the compounds according to the invention can be formulated notably by combination of these compounds with usual non-toxic excipients, according to methods which are well-known to the person skilled in the art, preferably so as to obtain medicaments which may be administered via the oral route, e.g. capsules or tablets. Practically, in case of administration of the compound via the oral route, the daily dosage in man will preferably be between 5 and 500 mg. Although the formulations in the form of capsules or tablets be preferred for reasons of comfort of the patient, the compounds according to the invention can also be prescribed in other galenic forms, e.g. if the patient does not accept or is not in a state to accept the solid oral formulations, or if the treatment necessitates a very rapid bioavailability of the active principle. It will therefore be possible for the medicament to be presented in the form of a drinkable syrup, or in injectable form, preferably sub-cutaneous or intramuscular.

Claims

1. A thiohydantoin derivative compound, characterised in that it is selected from: a) compounds of formula 844 in which R1 represents an aromatic ring which is non-substituted or substituted with one or more atoms or groups of atoms selected from halogens, linear or branched C1-C4 alkoxy, linear, branched or cyclic C1-C4 alkyl, linear or branched C1-C4 alkylthio, nitro, trifluoromethyl, trifluoromethoxy, methylenedioxy, or 845 groups, R2 represents: a hydrogen atom, a linear, branched or cyclic C1-C7 alkyl group, optionally having one or more oxygen atoms, a C1-C3 haloalkyl group, a linear or branched C3-C5 alkenyl group, a linear or branched C3-C4 alkynyl group, a C2-C6 hydroxyalkyl group, a C2-C4 aminoalkyl group, a C2-C3 cyanoalkyl group, a linear or branched C1-C3 alkyl group, which is substituted with one or more R7 substituents, or an aromatic ring which is non-substituted or substituted with one or more atoms or groups of atoms selected from halogens, linear or branched C1-C4 alkoxy, linear, branched or cyclic C1-C4 alkyl, linear or branched C1-C4 alkylthio, amino, cyano, hydroxy, nitro, trifluoromethyl, trifluoromethoxy, methylenedioxy, ethylenedioxy, difluoromethylenedioxy, aminosulphonyl, dimethylamino, C1-C3 hydroxyalkyl, carboxylic acid, C2-C3 alkyl ester, methanesulphonylamino, benzenesulphonylamino, t-butoxycarbonylamino, or 846 groups, R3, R5 and R6 each independently represent a hydrogen atom or a C1-C4 alkyl group, R4 represents a hydrogen atom, a C1-C4 alkyl group or a hydroxy group, or, R3 and R4 together form a methylene group, or R5 and R6 together form an ethylene group —CH2—CH2—, R7 represents a carboxylic acid group which is free or esterified with a C1-C3 alkyl group, a phenyl ring which is non-substituted or substituted with one or more methoxy, phenyl or methylenedioxy groups, a 2-furyl ring, a 2-, 3- or 4-pyridinyl ring or a 4-morpholinyl group, m=2 or 3, X represents an oxygen atom, a sulphur atom, a sulphoxide group, a sulphonyl group, a carbonyl group, a 847 group, or a: 848 group, R8 represents a hydrogen atom, a hydroxy group, a C1-C2 hydroxyalkyl group, a benzoyl group or a CO2CH3 group, R9 represents a hydrogen atom or forms, with R8, an ethylenedioxy group, and R10 represents a methyl group, a C2-C4 hydroxyalkyl group, a 1-oxo-C2-C4-alkyl group, an SO2N(CH3)2 group, a 2-pyridinyl group or a 2-pyrimidinyl group,  on the condition that at least one of the R1 and R2 substituents represents an aromatic ring which is substituted at least with a 849 group,  and b) addition salts of the compounds of formula I with an acid, notably pharmaceutically acceptable salts.

2. The compound according to claim 1, characterised in that it is selected from: a) compounds of formula 850 in which R1 represents a phenyl ring which is optionally substituted with one or more atoms or groups of atoms selected from halogens, linear C1-C4 alkyl or 851 groups, R2 represents a linear or cyclic C1-C7 alkyl group, a linear C3-C5 alkenyl group, or a phenyl, 2-thienyl or 3-pyridinyl ring, which is optionally substituted with one or more atoms or groups of atoms selected from halogens, linear or branched C1-C4 alkoxy, linear C1-C4 alkyl, linear C1-C4 alkylthio, amino, hydroxy, nitro, trifluoromethyl, trifluoromethoxy, methylenedioxy or 852 groups, R3 represents a hydrogen atom, a linear C1-C4 alkyl group, or a hydroxy group, R4, R5, and R6 each independently represent a hydrogen atom or a linear C1-C4 alkyl group, X represents an oxygen atom, a sulphoxide group or a carbon atom which is substituted with a C1-C2 hydroxyalkyl group,  on the condition that at least one of the R1 and R2 substituents represents an aromatic ring which is substituted at least with a 853 group,  and b) addition salts of compounds of formula I with an acid, notably pharmaceutically acceptable salts.

3. The compound according to claim 1, characterised in that R1 represents a phenyl group which is substituted in the para position with a

4. The compound according to one of claims 1 to 3, characterised in that X represents an oxygen atom.

5. The compound according to one of claims 1 to 4, characterised in that R3 represents a hydrogen atom and R4 represents a methyl group.

6. A method of preparing a compound according to any one of claims 1 to 5, characterised in that it comprises the steps consisting in: 1) allowing an amino acid of formula: 855in which R1 represents an aromatic ring which is non-substituted or substituted with one or more atoms or groups of atoms selected from halogens, linear or branched C1-C4 alkoxy, linear, branched or cyclic C1-C4 alkyl, linear or branched C1-C4 alkylthio, nitro, trifluoromethyl, trifluoromethoxy, methylenedioxy or 856 groups, m represents 2 or 3, X represents an oxygen atom, a sulphur atom, a sulphoxide group, a sulphonyl group, a carbonyl group, a 857 group, or a: 858 group, R3, R4, R5 and R6 each independently represent a hydrogen atom or a C1-C4 alkyl group, R8 represents a hydrogen atom, a hydroxy group, a C1-C2 hydroxyalkyl group, a benzoyl group or a CO2CH3 group, R9 represents a hydrogen atom or forms, with R8, an ethylenedioxy group, R10 represents a methyl group, a C2-C4 hydroxyalkyl group, a 1-oxo-C2-C4-alkyl group, an SO2N(CH3)2 group, a 2-pyridinyl group or a 2-pyrimidinyl group,  to react with an isothiocyanate of formula R2—N═C═S  (III) in which R2 represents a linear, branched or cyclic C1-C7 alkyl group, optionally having one or more oxygen atoms, a C1-C3 haloalkyl group, a linear or branched C3-C5 alkenyl group, a linear or branched C3-C4 alkynyl group, a C2-C6 hydroxyalkyl group, a protected C2-C4 aminoalkyl group, a C2-C3 cyanoalkyl group, a linear or branched C1-C3 alkyl group, which is optionally substituted with one or more R7 substituents, or an aromatic ring which is non-substituted or substituted with one or more atoms or groups of atoms selected from halogens, linear or branched C1-C4 alkoxy, linear, branched or cyclic C1-C4 alkyl, linear or branched C1-C4 alkylthio, cyano, hydroxy, nitro, trifluoromethyl, trifluoromethoxy, methylenedioxy, ethylenedioxy, difluoromethylenedioxy, aminosulphonyl, dimethylamino, C1-C3 hydroxyalkyl, carboxylic acid, C2-C3 alkyl ester, methanesulphonylamino, benzenesulphonylamino, t-butoxycarbonylamino, or 859 groups,  in a solvent, in the presence of an aprotic base, at a temperature of between 10° C. and the reflux temperature of the solvent, for 2 to 4 hours, to obtain the compound of formula I 860in which R1, R2, R3, R4 keep the same meaning as above, it being understood that at least one of the R1 and R2 groups contains in its structure an aromatic ring which is substituted at least by the 861 group, as defined above;  and, 2) if necessary, obtaining the addition salt of the compound of formula I above with an organic or mineral acid.

7. A method of preparing a compound according to any one of claims 1 to 5, characterised in that it comprises the steps consisting in 1) allowing an amino acid ester of formula (IIa) 862in which R1, R3 and R4 have a meaning which is analogous to that of the R1, R3 and R4 substituents which are noted for the compound of formula II which is described in the method A, and Ra represents a C1-C3 alkyl group, preferably an ethyl group,  to react with an isothiocyanate of formula R2—N═C═S  (III) as described above for the method A,  in a solvent, in the presence of a weak acid, at a temperature of between 50° C. and the boiling temperature of the solvent, for 2 to 25 hours, to obtain the compound of formula I 863in which R1, R2, R3, R4 keep the same meaning as above, it being understood that at least one of the R1 and R2 groups contains in its structure an aromatic ring which is substituted at least by the 864 group, as defined above;  and, 2) if necessary, obtaining the addition salt of the compound of formula I above with an organic or mineral acid.

8. A method of preparing a compound according to any one of claims 1 to 5, characterised in that it comprises the steps consisting in 1) allowing an amino acid ester of formula (IIa) 865in which R1, R3 and R4 have a meaning which is analogous to that of the R1, R3 and R4 substituents which are noted for the compound of formula II which is described in the method A, and. Ra represents a C1-C3 alkyl group, preferably an ethyl group,  to react with an isothiocyanate of formula R2—N═C═S  (III) as described above for the method A,  in the presence of a weak acid, under microwave radiation, for 2 to 15 minutes, to obtain the compound of formula I 866in which R1, R2, R3, R4 keep the same meaning as above, it being understood that at least one of the R1 and R2 groups contains in its structure an aromatic ring which is substituted at least by the 867 group, as defined above;  and, 2) if necessary, obtaining the addition salt of the compound of formula I above with an organic or mineral acid.

9. A pharmaceutical composition, characterised in that it contains, in combination with at least one physiologically acceptable excipient, at least one compound of formula I according to one of claims 1 to 5, or one of its addition salts with a pharmaceutically acceptable acid.

10. The compound of formula (I) according to any one of claims 1 to 5, or one of its addition salts with a pharmaceutically acceptable acid, for its use as a pharmacologically active substance.

11. Use of a compound of formula I according to one of claims 1 to 5, or one of its addition salts with a pharmaceutically acceptable acid, for the preparation of a medicament intended for treating diabetes or diseases caused by a hyperglycaemia.

12. Use of a compound of formula I according to one of claims 1 to 5, or one of its addition salts with a pharmaceutically acceptable acid, for the preparation of a medicament intended for treating hypertriglyceridaemiae and dyslipidaemiae.

13. Use of a compound of formula I according to one of claims 1 to 5, or one of its addition salts with a pharmaceutically acceptable acid, for the preparation of a medicament intended for treating obesity.

14. Use of a compound of formula I according to one of claims 1 to 5, or one of its addition salts with a pharmaceutically acceptable acid, for the preparation of a medicament intended for treating cerebral vascular accidents.